2009 . 2010

Innovation from cell to society

Networks of Centres of Excellence
AllerGen NCE Inc. is hosted at McMaster University, Hamilton, Ontario, Canada.

AllerGen NCE Inc. is supported by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.

The Networks of Centres of Excellence is a joint program of the Natural Sciences and Engineering Research Council of Canada, the Social Sciences and Humanities Research Council of Canada, the Canadian Institutes of Health Research and Industry Canada.

Launched in 1989 to manage the original Network of Centres of Excellence (NCE), today the NCE Secretariat runs four national initiatives: Networks of Centres of Excellence (NCE); Centres of Excellence for Commercialization and Research (CECRs); Business-Led Networks of Centres of Excellence (BL-NCEs); and Industrial Research and Development Internship program (IRDI).

**AllerGen NCE Inc.**

McMaster University  
Michael G. DeGroote Centre for Learning & Discovery  
1200 Main Street West, Room 3120  
Hamilton, ON  L8N 3Z5  

Telephone:  (905) 525-9140 ext.26502  
Fax:  (905) 524-0611  
E-mail:  info@allergen-nce.ca

[www.allergen-nce.ca](http://www.allergen-nce.ca)
AllerGen NCE Inc. was established in response to the fact that one in three Canadians have allergic diseases and that there was a dearth of research available about the causes of and treatments for asthma, allergy and related immune diseases. Since its inception in 2004, AllerGen has been fostering a national network comprising leading Canadian allergy and immune disease experts who are working collaboratively to reduce the morbidity, mortality and socio-economic impacts of allergy, asthma and related immune diseases.

Corporate Profile ...................................................................................................................................................................................................................3

  AllerGen's Vision.............................................................................................................................................................................................................3

  AllerGen's Mission .........................................................................................................................................................................................................3

Message from the Board Chair and Scientific Director .................................................................................................................................................................4

AllerGen Highlights from 2009-2010 .....................................................................................................................................................................................7

AllerGen's Integrated Research Programme .......................................................................................................................................................................11

  Strategic Research Highlights ......................................................................................................................................................................................15

  Cross-Programmatic Research Teams and Platforms ..................................................................................................................................................20

Innovation from Cell to Society® – AllerGen's Annual Research Conference ......................................................................................................................24

Network Partners and Collaborators .........................................................................................................................................................................................27

Knowledge and Technology Exchange and Exploitation (KTEE) .............................................................................................................................................31

Tomorrow’s Leaders: AllerGen’s Highly Qualified Personnel ..............................................................................................................................................36

Financial Overview ..............................................................................................................................................................................................................43

Network Participants 2009-2010 ...................................................................................................................................................................................................44
AllerGen-funded research aims to accelerate the development of new diagnostic tests, better medications and more effective public policies.
AllerGen NCE Inc. (AllerGen), the Allergy, Genes and Environment Network, is a national research network funded by Industry Canada through the Networks of Centres of Excellence (NCE) Program. AllerGen supports excellence in research and fosters social innovation and knowledge translation that will enable Canadians to better prevent, manage and treat allergy, asthma, anaphylaxis and related immune diseases.

Through the creation of a national network of allergy and immune disease experts, AllerGen brings together more than 269 investigators and collaborators, 394 students and young professionals and 164 full-time equivalent network research personnel. In addition, AllerGen works closely with over 164 partners across different sectors, including academic, industry and government, on 52 research projects.

AllerGen-funded research aims to accelerate the development of new diagnostic tests, better medications and more effective public policies. AllerGen’s investments in education and training improve public education, allergy, asthma and anaphylaxis management and increase the number of medical professionals researching and practicing in these areas.

AllerGen’s Vision
To create an enduring network of allergy and immune disease experts whose discovery and development efforts contribute to reductions in the impact of allergic and related immune diseases nationally and globally.

AllerGen’s Mission
To catalyze and support discovery, development, networking, capacity building, commercialization and knowledge translation that contribute to reducing the morbidity, mortality and socio-economic burden of allergic and related immune diseases.
Message from the Board Chair and Scientific Director

AllerGen NCE Inc. was established in response to the fact that one in three Canadians have allergic diseases and that there was a dearth of research available about the causes of and treatments for asthma, allergy and related immune diseases. Since its inception in 2004, AllerGen has been fostering a national network comprising leading Canadian allergy and immune disease experts who are working collaboratively to reduce the morbidity, mortality and socio-economic impacts of allergy, asthma and related immune diseases. It is with great pleasure that we present our fifth Annual Report for the period April 1, 2009 to March 31, 2010 which outlines the many achievements accomplished within the Network’s strategic priority areas over this past year.

AllerGen-funded research aims to understand the causes of allergy and asthma, accelerate the development of new diagnostic tests and better medications, and provide the evidence to support more effective public policies, with the ultimate goal of reducing the burden of these diseases on Canadian society, and improving the lives of those who live with them.

AllerGen-funded research aims to understand the causes of allergy and asthma, accelerate the development of new diagnostic tests and better medications, and provide the evidence to support more effective public policies, with the ultimate goal of reducing the burden of these diseases on Canadian society, and improving the lives of those who live with them. In July 2009, AllerGen awarded approximately $11 million to 20 research teams at 15 hospitals and academic institutions
across Canada investing in multi-disciplinary, networked and partnered programmes of research that aim to better understand, prevent, control or eliminate allergies, asthma, anaphylaxis and related immune diseases.

2009-2010 was a year of continued growth and maturation for AllerGen. Since 2008-2009 the number of AllerGen partners participating in the Network increased by 35%; the number of highly trained professionals, by 26%; the number of publications, by 46%; and, the overall number of allergy and immune disease experts working on AllerGen-funded projects, by 31%.

As a highly integrated, multi-disciplinary and multi-sectoral national research network, AllerGen has established strong ties with international organizations and academic institutions. This has been facilitated through AllerGen’s successful implementation of an International Partnership Initiative (IPI) totalling over one million dollars, supported by the NCE Program and by the International Development Research Centre. This past year, AllerGen initiated additional collaborative partnerships aimed at extending its international outreach by developing collaborations with networks of genetic, environmental, allergy and asthma researchers in Germany, China and Australia.

AllerGen’s investments in education and training improve public education, allergy, asthma and anaphylaxis management and increase the number of medical professionals researching and practicing in these areas. AllerGen has also been actively promoting knowledge translation (KT) and knowledge mobilization initiatives that accelerate the sharing of Network research findings with research users across sectors, the general public and other stakeholders.

This year’s annual report highlights AllerGen’s key achievements from 2009-2010. Our achievements to date position AllerGen as the leader in mobilizing Canadian research, social innovation and knowledge translation that will enable Canadians to better prevent, manage and treat allergy, asthma, anaphylaxis and related immune diseases.

We extend our sincere congratulations and appreciation to the entire AllerGen community for their ongoing commitment and contributions to the Network and in addition, we would like to acknowledge the invaluable contributions of the AllerGen Board of Directors, remembering particularly Dr. Gloria Jordana, who passed away in an untimely manner on June 5, 2010.

Graham Scott, C.M., Q.C.
Chair, Board of Directors

Judah Denburg, MD, FRCP(C)
Scientific Director and CEO
AllerGen’s investment in Genapha is facilitating the development of novel user interactions with the recently collected genetic data thus enhancing allergy, asthma and related immune disorder research.
Dr. Denise Daley and her team of researchers from the University of British Columbia brought together genetic data from four asthma studies involving 5,565 individuals from Canada and Australia. These individuals were genotyped for 162 asthma candidate genes and related phenotypes. More than 12.3 million genotypes were generated by these four studies.

GENAPHA – A Global Resource for Allergy and Asthma Researchers

Genapha, www.genapha.ca, is an interactive website database that supports the world’s largest candidate gene study of asthma and allergy. Dr. Denise Daley and her team of researchers from the University of British Columbia brought together genetic data from four asthma studies involving 5,565 individuals from Canada and Australia. These individuals were genotyped for 162 asthma candidate genes and related phenotypes. More than 12.3 million genotypes were generated by these four studies.

AllerGen funding allowed the team to expand the Genapha database from a simple, static repository of information into an interactive, knowledge sharing, globally accessible database. Genapha is designed to easily communicate and disseminate knowledge from the database about common complex diseases and engage the public in issues such as the genetics of asthma/allergy, genetic testing and pharmacogenetics. Genapha also allows researchers using animal models or cell cultures access to well-organized and phenotyped human populations and cohorts. Tools allow visitors to search the site for information in a variety of different ways, enabling them to utilize the information to develop and test their own hypotheses.

AllerGen’s investment in Genapha is facilitating the development of novel user interactions with the recently collected genetic data thus enhancing allergy, asthma and related immune disorder research.

Surveying Canadians to Assess the Prevalence of Common Food Allergies and Attitudes towards Food Labelling and Risk (SCAAALAR)

The Surveying Canadians to Assess the Prevalence of Common Food Allergies and Attitudes towards Food Labelling and Risk (SCAAALAR) Study provides unique insight into the prevalence and determinants of food allergy in Canada. A gap exists between the unexplained increase in food allergy in the Canadian population and the need for enhanced education of all segments of society about food allergy including appropriate policy responses. Drs Ann Clarke (McGill University) and
AllerGen researchers concluded that socio-economic status and birthplace influence food allergy prevalence.

Results from the SCAAALAR Study will be used to:

1) Ensure that sufficient health and educational resources are allocated to the prevention, diagnosis and management of allergic diseases in Canada;

2) Disseminate guidelines regarding increased use of confirmatory tests and food challenges, contributing to more accurate diagnosis;

3) Guide educational institutions in developing policies to prevent and manage anaphylaxis, further contributing to increased safety in the classroom for those students who are allergic; and

4) Assist food industries in revising food labels on commercial food products making food labelling more consistent and comprehensible, another contributing factor to ensure the safety of those who suffer from food allergies.

AllerGen funding has been used to help disseminate the results of this study through participation in a variety of research meetings, conferences, workshops and meetings with policy makers. AllerGen’s networked approach allowed for the data collected to be translated for use by key policy makers at Health Canada who, in turn, both co-funded the research and employed the data obtained in the policy making process on food labelling. Health Canada continues to be a key partner in the next phase of this study.

Susan Elliott (University of Waterloo) utilized AllerGen funding to launch the SCAAALAR study in 2008, to obtain data on the prevalence and determinants of common food allergies and characterize the broader societal response to its apparent increasing frequency. This cross-Canada telephone survey resulted in the first nationwide information about Canadian prevalence of food allergies (to peanut, tree nut, fish, shellfish, and sesame).
AllerGen’s Knowledge Translation Planning Tools for Allergic Disease Researchers

Launched in December 2009, the AllerGen Knowledge Translation Planning Tools for Allergic Disease Researchers (KT Tool) was developed to assist allergy, asthma and anaphylaxis researchers, research trainees and their collaborating partner organizations to develop a knowledge translation plan for research projects from the onset of their research collaborations.

AllerGen’s KT Tool can be applied across disciplines to develop effective knowledge translation plans for research projects, optimizing social and economic research benefits. The KT tool is available on the AllerGen website, www.allergen-nce.ca, and has been distributed in hard copy at its Network-wide research conference, the Ontario Asthma Plan of Action Forum and was the focus of an interactive session on using the tool at an AllerGen trainee capacity building workshop.

Online Anaphylaxis Training for Schools Developed

Recognizing that there are deficiencies in anaphylaxis policy and training provided in elementary and secondary schools, AllerGen supported the development of an e-learning program by Dr. Anthony Levinson, Assistant Professor at McMaster University.

This program of online courses directed at teachers, daycare staff, and restaurant managers and personnel is based on best practices for dealing with anaphylactic individuals. Since school-based training capacity is limited and costly, e-learning is an efficient, cost-effective model for human resource training on how to deal with anaphylaxis in the educational setting.

The program has learning modules dedicated to the following areas:

- Policy and legal issues surrounding anaphylaxis and food allergy;
- Understanding anaphylaxis, including identifying signs and symptoms;
- How to respond to an anaphylactic emergency and using an auto-injector;
- Reducing risk in schools; and
- Providing additional resources and information on anaphylaxis.

Dr. Levinson has built upon his AllerGen-supported project in partnership with the Government of Alberta in order to implement this e-learning program, called the Alberta Education Pilot Study. Following an evaluation process, the team will explore opportunities to roll-out customized adaptations of this tool in other jurisdictions and provinces.
AllerGen’s goal is to catalyze and support innovative research that contributes to the discovery of the causes of, and ways to prevent, control or eliminate allergic and related immune diseases.
AllerGen’s Integrated Research Programme

AllerGen’s national network allows for novel collaborations to take place amongst leading research experts fostering cutting-edge, multi-disciplinary research. AllerGen’s integrated research programme is spearheaded by six internationally recognized researchers providing leadership to three cross-cutting research platforms.

Since 2005, AllerGen has supported a broad spectrum of research aimed at radically improving the quality of life for allergy, asthma and related immune disease sufferers.

It is AllerGen’s goal to catalyze and support innovative research that contributes to the discovery of the causes of, and ways to prevent, control or eliminate allergic and related immune diseases. AllerGen’s national network allows for novel collaborations to take place amongst leading research experts fostering cutting-edge, multi-disciplinary research.

AllerGen’s integrated research programme is spearheaded by six internationally recognized researchers providing leadership to three cross-cutting research platforms:
Programme A
– Gene-Environment Interactions
Programme Leaders:
Jeffrey Brook, PhD, Environment Canada
Peter Paré, MD, University of British Columbia
Strategic Focus:
Genetics, environmental exposures and gene-environment interactions in allergy and asthma
AllerGen’s Gene-Environment Interactions research programme aims to capitalize on the wealth of data concerning early life phenotypes by pooling data across existing cohorts, focusing on genetic polymorphisms in genes related to early life allergic processes and establishing a new Canadian allergy and asthma birth cohort, the Canadian Healthy Infant Longitudinal Development (CHILD) Study. The CHILD Study is a partnered study with funding from AllerGen, Canadian Institutes of Health Research (CIHR) and other stakeholders. In addition, this programme aims to determine the ‘prime-candidate’ environmental events and exposures during infancy and early childhood involved in the development and perpetuation of a predisposition to allergic disease, as well as to investigate the interaction of airborne pollutants and allergens, study the role of infection in allergy/asthma and study prevalence and expression of allergy/asthma in specific Canadian populations.

Programme B
– Diagnostics and Therapeutics
Programme Leaders:
Dean Befus, PhD, University of Alberta
Paul O’Byrne, MB, FRCP(I), FRCP(C), FRCP(E), FRCP(Glasg), McMaster University
Strategic Focus:
Biomarkers, immune monitoring and drug development/discovery
AllerGen’s Diagnostics and Therapeutics research programme aims to identify indicators of asthma and allergic disease, develop effective monitoring methods and to test and develop new therapeutics to treat allergy, asthma and immune-related diseases. Programme B also aims to move biomarkers and immune monitoring science out of the laboratory and apply them to the development of new therapies and drug targets in a clinical setting.

Programme C
– Public Health, Ethics, Policy and Society
Programme Leaders:
Susan Elliott, PhD, University of Waterloo, formerly of McMaster University
Allan Becker, MD, University of Manitoba

**Strategic Focus:**
Allergic disease management and surveillance

AllerGen’s Public Health, Ethics, Policy and Society research programme aims to assess current legal frameworks, policies and education systems, as well as prevalence and perception issues, to fill knowledge gaps and enable evidence-based policy and practice to improve disease management and public health. The programme also aims to further the investigation of psychosocial impacts and the health economics of allergic diseases, including food allergy, allergic rhinitis, asthma and anaphylaxis to inform policy and practice.

AllerGen strives to achieve its mandate of investing in innovative and results-focused allergic and related immune disease research. In order to realize this mandate, AllerGen has developed four cross-programmatic, multi-disciplinary research platforms:

**Cross-Programmatic Research Teams and Platforms**

**Established Cross-programmatic Teams**

**The Canadian Healthy Infant Longitudinal Development (CHILD) Study**

*Research Leaders:*
Malcolm Sears, MB, ChB, FRACP, FAAAAI, McMaster University
PJ Subbarao, MD, MSc, FRCP(C), University of Toronto
Jean Marshall, PhD, Dalhousie University

**Food Allergy and Anaphylaxis**

*Research Leader:*
Jean Marshall, PhD, Dalhousie University

**Emerging Cross-programmatic Teams**

**Mind-Body Interactions and Allergic Disease**

*Research Leader:*
Diane Lougheed, MD, MSc, FRCP(C), Queen’s University

**Occupational and Work-related Allergy and Asthma**

*Research Leader:*
Diane Lougheed, MD, MSc, FRCP(C), Queen’s University
In addition to the development of a transferable traffic pollution model, which could have international benefit, Dr. Brauer’s research is adding significant value to research on other diseases beyond asthma.
Programme A
– Gene-Environment Interactions
Traffic-related air pollution as a risk factor for the development of childhood asthma
What impact does traffic-related air pollution have on the development of asthma in children? Dr. Michael Brauer, Professor, Department of Medicine, School of Environmental Health at the University of British Columbia and his research team are engaged in cutting-edge research that will provide them with:

i. An understanding of the role of traffic-related air pollution in the development of childhood asthma;
ii. An appreciation of the role of genetic factors in the initiation of childhood asthma by traffic-related air pollution;
iii. An assessment of trends in spatial patterns of traffic-related air pollution in two major Canadian cities (Vancouver and Toronto); and
iv. A leadership role for AllerGen and Canadian researchers in international collaborative efforts related to gene-air pollution interactions and asthma.

During the initial phase of the research project, Dr. Brauer’s team produced maps of long-term average traffic-generated air pollution concentrations in Edmonton, Alberta and Winnipeg, Manitoba. These maps are based on models that predict pollution concentrations from data on land use, road configurations, topography and other spatial predictors and provide a tool for estimating exposure to traffic-generated air pollution based on locations such as residences or schools. The maps will be used to estimate exposure in the CHILD Study, which examines the influences of environmental factors on children’s health.

One of the unique aspects of this work is the simultaneous development of models that analyze traffic-generated air pollution exposure and asthma development for two different cities, Winnipeg and Vancouver, using common data collection and modeling techniques. This allowed for the evaluation of the “transferability” of traffic pollution prediction models between cities, which has been identified as an important research need.

In addition to the development of a transferable traffic pollution model, which could have international benefit, the team’s research is adding significant value to research on other diseases beyond asthma. The team is collaborating with a Health Canada research group that is using its Edmonton map in an analysis of the relationship between air pollution exposure and risk of stroke, as well as a multi-disciplinary team of researchers based at the School of Environmental Health, University of British Columbia for a study on the relationship between environmental and occupational exposures and cancer.

This research project will continue until 2012 with the goal of determining if exposure to traffic-related air pollution (TRAP) increases the risk of incident asthma in children and to develop and apply infrastructure to investigate gene-environment interactions related to asthma and allergy. This project’s success is in large part due to AllerGen’s extensive networking of experts in environmental exposure, epidemiology, asthma/allergy and genetics in Canada and internationally.

Programme B:
Diagnostics and Therapeutics
Cross-programmatic successes facilitated by the AllerGen Clinical Investigator Collaborative (CIC): focus on the genetics of the early and late responses to an allergen challenge
AllerGen’s CIC, a national clinical trials consortium, led by Dr. Paul O’Byrne, EJ Moran Campbell Professor in Respirology Medicine and Chair,
Department of Medicine at McMaster University, began in 2005 with AllerGen support. Now in its fifth year, the AllerGen CIC has expanded its research and clinical trial collaborations globally, with satellite sites in Stockholm, Sweden and Rotterdam, Netherlands. The AllerGen CIC provides an important commercial advantage to pharmaceutical and biotechnology companies, both large and small, by assisting them with their decisions about the clinical advancement of potential new therapies for asthma. The CIC offers one of the best teams in the world when it comes to conducting Phase II trials for new therapeutics, and the key to its success is the quality of the associated research it conducts.

The AllerGen CIC has three main research objectives:

i. To use selective pharmacological tools to understand the pathobiology of allergen-induced airway responses and airway inflammation.

ii. To study the activity of potential new therapies for asthma.

iii. To provide blood and tissue samples from well-phenotyped mild allergic asthmatic subjects to other investigators within the AllerGen network, to help better understand the mechanisms of allergic asthma.

The AllerGen CIC agreed to undertake three studies with novel approaches to treat asthma in 2009-10. Each of these studies had a strong pre-clinical rationale for evaluating the molecule in allergic asthmatic subjects. An allergen inhalation challenge was used in each of the studies to examine the activity of the molecule in asthmatic airways.

The allergen challenge protocol of the CIC has consistently proven itself to be a useful research tool since its inception.
The AllerGen CIC provides an important commercial advantage to pharmaceutical and biotechnology companies, both large and small, by assisting them with their decisions about the clinical advancement of potential new therapies for asthma. The CIC offers one of the best teams in the world when it comes to conducting Phase II trials for new therapeutics, and the key to its success is the quality of the associated research it conducts.

and clinical tool for evaluating allergic diseases such as asthma by confirming allergic responses to specific allergens, investigating the mechanisms of disease and evaluating the effectiveness of potential therapies. The CIC Allergen Inhalation Challenge is undertaken in collaboration with AllerGen genetics researcher, Dr. Scott Tebbutt, Assistant Professor at the University of British Columbia. Dr. Tebbutt and his research team are investigating the functional genomics, proteomics and ultimately the genetic basis of the physiological and cellular characteristics of allergic responses to allergen challenge. They are looking at three populations: one from a study in the AllerGen CIC, another from the Environmental Exposure Unit (EEU) at Kingston General Hospital/Queen’s University and a third from the Western Red Cedar Asthma Cohort (WRCA) at the University of British Columbia. Tebbutt has a particular interest in why some individuals, when exposed to an allergen (via inhalation), develop an isolated early response while other individuals develop both early and late phase responses.

Dr. Tebbutt and his team have successfully gathered samples from challenged atopic asthmatic individuals in the CIC Allergen Inhalation Challenge. Approximately 70 subjects were recruited, challenged and sampled for DNA, RNA and plasma (from blood) at two time points (pre- and post-challenge).

During the next phase of this project, Dr. Tebbutt and his team are working towards a detailed analysis of the phenotypes from the CIC (and EEU) cohorts. Findings to date will allow researchers to appropriately select matched subject samples for pilot molecular analyses, including plasma lipids and cytokines, and blood cell gene expression. Recruitment, challenge and sampling will continue for the CIC and WRCA cohorts.

This initiative and the work of the CIC represent a collaborative effort between two of AllerGen’s Integrated Research Programmes: Gene-Environment Interactions (Programme A) and Diagnostics and Therapeutics (Programme B). In summary, the AllerGen CIC has made available to Canadian investigators across the country, highly selective molecules to study the pathobiology of allergen-induced airway responses. In addition, the CIC has resulted in Canada becoming recognized by pharmaceutical companies as the global leader in evaluating potential new asthma therapeutics. Finally, operating with an AllerGen budget of $2 million to date, the CIC has
leveraged approximately five additional partner dollars for every AllerGen dollar of investment, for a total investment of over $12 million in clinical trials research undertaken in Canada.

**Programme C:**
**Public Health, Ethics, Policy and Society**
**Engaging Aboriginal families affected by allergies and asthma in support and educational program development**

Despite higher rates of asthma and allergies in Aboriginal youth, which negatively impact quality of life and psychosocial wellbeing, accessible interventions that focus on the specific support needs and preferences of affected families are non-existent.

No study to date has investigated the resources, support, education needs and intervention preferences of affected Aboriginal adolescents and parents. AllerGen investigator, Dr. Miriam Stewart, Professor at the University of Alberta is determined to change this.

Dr. Stewart is building upon two AllerGen-funded pilot projects that she has conducted to investigate the social support needs and preferences of non-aboriginal children and adolescents with asthma and/or anaphylaxis and their parents as well as to engage Aboriginal families affected by allergies and asthma in the development of support and educational programs.

The research being conducted expands the scope of the initial pilot studies by:

i. Focusing on the support needs of Aboriginal adolescents with asthma and allergies and their parents;

ii. Designing and pilot-testing an innovative accessible support and education intervention that meets these needs, in collaboration with Aboriginal stakeholders; and

iii. Building pertinent partnerships in Alberta, Manitoba and Nova Scotia.

This three-phase study is being conducted by an inter-disciplinary team based in Alberta and will include:

i. A four-day *Allergy Asthma Camp* that will be facilitated by an Aboriginal asthma educator and a community representative;

ii. Input from stakeholder groups on appropriate support interventions; and
iii. Discussion of study findings and knowledge translation strategies through a ‘co-learning’ format.

Notable project milestones are that:

• A Community Advisory Committee was established in Alberta comprising academics, school and community officials and Elders.
• Relationships were built and approval was gained for the study from Aboriginal community and school officials representing four Eastern Métis Settlements and two First Nations communities within Alberta.
• Support has been secured from selected schools within Edmonton Public Schools and has received approval from the Cooperative Activities Program.
• The study has been presented at various school and community events focused on Aboriginal children and their parents.
• Opportunities were created for six Aboriginal Community Research Assistants to develop research skills and represent the study at various community and school events, and network with health care providers or Aboriginal people who can assist with recruitment.
• Fifty-eight interviews have been conducted with Aboriginal children who have allergies and asthma and their parents, half of which have been transcribed and are being used for data analysis.
• Successful grant applications were submitted to CIHR and the Alberta Centre for Child, Family and Community Research (ACCFCR), resulting in supplementary research funding.

The research being conducted by Dr. Stewart and her team is advancing AllerGen’s goal to undertake research on asthma and allergy in Canada’s Aboriginal communities. Through an improved understanding of the social, cultural and economic burden of asthma, allergies and related immune diseases, this research is translating evidence into practice that will improve the quality of life for aboriginal people.
The Canadian Healthy Infant Longitudinal Development (CHILD) Study

The Canadian Healthy Infant Longitudinal Development (CHILD) Study is a pan-Canadian study that is gathering data and samples related to the early life development of allergy, asthma and other environmentally-triggered diseases. Led by Dr. Malcolm Sears, Professor of Medicine at McMaster University, the study aims to follow 5,000 Canadian children for six years, from pre-birth to age five. It is the largest longitudinal birth cohort study in Canada and among the most important such studies in the world, as it has a high potential for breakthrough discoveries about the environmental triggers for asthma, allergy and related immune diseases.

Formal recruitment for the CHILD Study began in July 2009 and during 2010, over 500 participants were successfully recruited. Recruitment numbers for the CHILD Study continue to grow on a daily basis tracking towards the goal of over 1,000 recruits by September 2010.

With research suggesting that there are many environmental factors that may affect a child’s risk of developing asthma, allergies or related immune diseases, more research is needed to help us better prevent and manage these diseases. The CHILD Study will provide a wide spectrum of information from participating Canadian families and will determine which environmental factors potentially affect the health of Canadian children.

Site leaders for the CHILD Study are:

**Alberta:** P Mandhane, MD, University of Alberta

**Manitoba:** A Becker, MD, University of Manitoba

**Toronto:** PJ Subbarao, MD, MSc, FRCP(C), The Hospital for Sick Children

**Vancouver:** S Turvey, MBBS, DPhil, FRCP(C), University of British Columbia

Four study centres: Vancouver, Edmonton, Winnipeg and Toronto, are responsible for collecting and maintaining the massive data-set that will allow researchers to track the onset of allergic diseases across a large group of individuals. Ultimately, the information that the CHILD Study generates will lead to a far greater understanding of the causes of asthma, allergy and related immune diseases.

Cross-Programmatic Research Teams and Platforms
Food Allergy and Anaphylaxis

Canadian Group on Food Allergy Research (CanGoFAR)

AllerGen investigators, immunology experts, clinical allergists, toxicologists, geneticists and others from across Canada are collaborating through CanGoFAR with their research effort directed towards the development of new approaches to understanding and managing food allergy. The goal of AllerGen’s research investments in Food Allergy and Anaphylaxis is to understand its prevalence, triggers, pathogenesis and disease management, refine diagnostic and treatment strategies, inform evidence-based public policy and ultimately reduce risk and improve safety for food allergy sufferers in Canada.

The current CanGoFAR research project has three main aims:

i. Clinical trials and new tolerance targets: A team approach will be used to investigate how severe reactions to food can be prevented in a clinical setting through a preliminary trial in 30 subjects, using very low, repeated doses of allergenic foods given under carefully controlled conditions to ensure safety.

ii. Effector mechanisms and novel therapies: Studies that have been completed by CanGoFAR investigators and others have shown that two substances — platelet-activating factor (PAF) and histamine, may have a particularly important role in severe food allergy reactions. CanGoFAR is further examining the importance of these two substances in order to translate findings to the clinical setting, using agents that can block the action of these molecules.

iii. Collaboration with food industry/government agencies: The CanGoFAR team will work with the food industry and government bodies to develop safer foods for allergic individuals, and strategies to prevent the development of food allergies, which may involve modified foods and changes to public policy.

The following high-value achievements have been realized by the CanGoFAR team as a result of this research project:

• Relationships have been developed and discussions are ongoing with food and seafood companies;
• Extended interactions have occurred with clinicians performing oral challenge studies internationally;
• A network of Canadian researchers with a focus on food allergy has been fostered;
• Connections have been established with Canadian and international researchers with expertise in metabolomics and proteomics, who are applying these technologies to people with peanut allergy;
• Regular interactions with community-based allergy and anaphylaxis organizations in Canada have been established; and
• Enhanced interactions with international peanut allergy and anaphylaxis organizations such as the Food Allergy Initiative in the United States have been enabled.

The impacts anticipated from the AllerGen CanGoFAR research project include:

i. A better understanding of the requirements for the development of tolerance versus sensitization to target foods (e.g., peanuts) including identification of biomarkers associated with the development of de-sensitization during the course of oral immunotherapy;

ii. Improved tools for the diagnosis of food allergy, especially peanut allergy;
iii. Identification of biomarkers for severe/anaphylactic reaction to foods; and
iv. Improved interactions between the food industry, regulating agencies and university/hospital-based food allergy researchers.

### Mind-Body Interactions and Allergic Disease

#### Maternal distress and the development of atopic disease in children: Potential pathways and interventions

AllerGen’s *Mind-Body Interactions and Allergic Disease* investigators are examining the connections between potential asthma and allergy triggers and interactions with brain activity. Mind-body research is conducted in each of AllerGen’s three research platforms, Programmes: *Gene-Environment Interactions* (Programme A), *Diagnostics and Therapeutics* (Programme B) and *Public Health, Ethics, Policy and Society* (Programme C) and has a direct application to the CHILD Study.

Traditional environmental risk factors do not fully explain the increase in asthma and atopy in developed countries. Dr. Anita Kozyrskyj, University of Alberta, is conducting research on a little-studied lifestyle theory. Building upon previously supported AllerGen research, which indicated that exposure to maternal stress in early childhood is associated with the development of childhood asthma, Dr. Kozyrskyj is interested in learning more about the role of maternal stress on asthma development.

Researchers found that the risk for asthma at age seven increased by 30% following persistent exposure to maternal distress in early life. Depression has been identified as the main “toxic” component of maternal distress. Depressed mothers are more likely to smoke, less likely to breastfeed and less likely to interact with their infants, but it is not known whether or not these behaviours contribute to allergic disease in children.

Dr. Kozyrskyj’s current research focus is to assess the likelihood of asthma developing in nine and ten year old children who have been exposed to maternal stress in the first year of life; the goal is to contribute new data that will support related public policy recommendations.

A secondary objective of the research will be to assess the effectiveness of an intervention (peer and nursing support) in reducing rates of allergic disease in children. These objectives will be tested using data from pre-and post-natal public health support programs in western Canada.

Knowing if the association between maternal postpartum distress and childhood asthma has a
genetic basis carries significant societal implications. Preliminary findings from the Study of Asthma Genes and the Environment (SAGE) suggest a gene-environment interaction. Additional funding from CIHR has enabled the creation of an online survey that was distributed to mothers of SAGE children in 2009. Once analyzed, this will be the first evaluation to look at the impact of research on maternal mental health determinants of childhood asthma and its relationship to women’s beliefs and future behaviour. Findings from Dr. Kozyrskyj’s research will expand the current understanding of the role that maternal stress has on childhood asthma development and will lead to improved disease management.

The long-term aim of AllerGen’s Mind-Body Interactions and Allergic Disease research is to decrease the impact of allergic disease through enhanced evidence-based public health intervention strategies.

Occupational and Work-related Allergy and Asthma

Work-Related Allergy and Asthma: Prevention and Early Detection (WRAAPED) Research Program

AllerGen’s Occupational and Work-related Allergy and Asthma team aims to: identify the economic and social impacts of occupational and work-related allergy and asthma; further understand the mechanisms involved in occupational and work-related asthma; develop Canadian prevalence data; inform healthy public policy; and, increase the use of improved diagnostic and prevention strategies and tools.

The objectives of the Work-Related Allergy and Asthma: Prevention and Early Detection (WRAAPED) project are to:

i. Estimate the burden of work-related asthma (WRA) using administrative databases.
ii. Estimate the burden and under-recognition of WRA by applying percentages to a newly-developed administrative database in Ontario of patients with current asthma, and linking this database to provincial compensation databases.
iii. Quantify WRA morbidity in Quebec and Ontario and examine the impact of provincial differences in diagnostic approaches and compensation systems relative to timeliness of diagnosis and patterns of health care utilization.
iv. Improve detection of WRA in primary care settings by conducting a controlled study of the impact of a WRA screening tool and algorithm developed with previous AllerGen funding, on detection and recognition of WRA. Patient-related outcomes such as health care utilization and quality of life will also be assessed.

v. Extend previous research of compensation file reviews to the next five years of data (2002-2007). Trends in work-exacerbated asthma and occupational asthma over time will be analyzed with the goal of identifying factors associated with under-recognition and under-reporting to compensation boards.

The WRAAPED Research Program is a novel initiative since, in addition to the cross-Canadian team of experts committed to the project; it includes inter-provincial and inter-ministerial collaborations.

AllerGen’s Occupational and Work-related Allergy and Asthma team unites leading researchers across Canada with expressed interests in asthma, occupational lung disease, population health and knowledge translation.
Fostering Knowledge Translation and Exchange

AllerGen's Fifth Annual Research Conference, *Innovation from Cell to Society*, was held in Québec City from February 7-9, 2010. The conference attracted 190 national and international delegates from across sectors: industry, government, clinical, academic and not-for-profit.

Invited keynote speakers included Dr. Stephen Holgate, Southampton General Hospital, UK, a world-renowned researcher in applying basic science to the clinical interface in asthma and allied disorders; Dr. Neal Cohen, University of California, San Francisco, leading thinker on the development of partnerships between academia and industry; and Dr. Alan James, Sir Charles Gairdner Hospital and Hollywood Private Hospital, Australia — an AllerGen international research collaborator and expert in respiratory medicine.

Representatives from three of AllerGen’s international partner organizations: St. John’s Research Institute in Bangalore, India; the Karolinska Institute in Sweden; and the University of Western Australia, also attended the conference, showcasing AllerGen’s successful outcomes from the NCE’s International Partnership Initiative (IPI). Throughout the three-day conference, Canadian researchers and trainees were able to engage with these distinguished experts about their research advances and insights.

Trainee posters were presented, with authors of the top two posters from each of AllerGen’s three research programmes being invited to give oral presentations to conference delegates. The poster competition and oral presentations gave trainees, Canada’s future research leaders, the opportunity to showcase their research and
receive constructive feedback from AllerGen investigators, partner organization representatives, and other stakeholders.

Keynote speaker, Dr. Neal Cohen, delivered a thought-provoking presentation on open innovation networks between academia and industry, which featured AllerGen industry partner respondent Dr. Catherine Tribouley (Research Fellow, Molecular Profiling, Merck Research Laboratories). This interactive presentation format highlighted key partnerships between academic and industrial sectors that have been fostered by AllerGen.

Patient advocates play an integral role in driving change “from cell to society.” An important voice for food allergy risk reduction at AllerGen’s Annual Research Conference was that of Ms. Sara Shannon, who had lost her daughter and only child, Sabrina Shannon, to an anaphylactic reaction in 2003. Sara was the leading force behind groundbreaking Ontario legislation, Sabrina’s Law, to protect children at risk, and is well known and respected for her advocacy work regarding the rights of children at risk for anaphylaxis both nationally and globally. Sara participated in round table discussions at the conference, offering her personal experience and expertise on anaphylaxis safety.

International partners from St. John’s Research Institute, Bangalore, India attended AllerGen’s 2010 Annual Research Conference to further their collaboration with AllerGen researchers and trainees shown above.

<table>
<thead>
<tr>
<th>Conference Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special acknowledgement goes out to all of the sponsors for their generous support of <em>Innovation from Cell to Society</em>® – they make AllerGen’s Annual Conference possible.</td>
</tr>
<tr>
<td><strong>Gold Sponsors:</strong> GlaxoSmithKline, King Pharmaceuticals</td>
</tr>
<tr>
<td><strong>Silver Sponsors:</strong> McMaster University, Merck, Novartis</td>
</tr>
<tr>
<td><strong>Media:</strong> Longwoods.com</td>
</tr>
<tr>
<td><strong>Supporters:</strong> Allergy/Asthma Information Association, Asthma Society of Canada, Canadian Thoracic Society, Canadian Allergy, Asthma and Immunology Foundation</td>
</tr>
</tbody>
</table>
AllerGen aims to foster and maintain networking and partnership arrangements that enable knowledge and technology exchange and reposition Canada at the forefront of innovation.
The 2009-2010 year was one of continued growth and maturation for AllerGen. Since 2008-2009 the number of AllerGen partners participating in the Network increased by 35% and the number of highly trained professionals, by 26%.

**Network Partners and Collaborators**

**Academic Institutions: 36**
- American University
- Brandon University
- Charité-University Medicine Berlin
- Dalhousie University
- Groningen University
- Harvard University
- Indiana University
- McGill University
- McMaster University
- Mt. Sinai School of Medicine
- Purdue University
- Queen’s University
- Simon Fraser University
- Université de Montréal
- Université du Québec à Chicoutimi
- Université Laval
- University of Alberta
- University of Bristol
- University of British Columbia
- University of Calgary
- University of California
- University of Guelph
- University of Illinois at Chicago
- University of Manchester
- University of Manitoba
- University of New Brunswick
- University of North Carolina at Chapel Hill
- University of Ottawa
- University of Oxford
- University of Saskatchewan
- University of Tasmania
- University of Toronto
- University of Waterloo
- University of Western Australia
- University of Western Ontario
- Utrecht University

**Hospitals and Healthcare Centres: 27**
- BC Children’s Hospital (Vancouver)
- BC Women’s Hospital & Health Centre (Vancouver)
- Credit Valley Hospital (Mississauga)
- Grey Nuns Community Hospital (Edmonton)
- Hamilton Health Sciences
- Hôpital du Sacré-Cœur de Montréal
- Hôpital Ste-Justine (Montreal)
- Institut universitaire de cardiologie et de pneumologie de Québec
- IWK Health Centre (Halifax)
- Kingston General Hospital
- Manitoba Institute of Child Health
- McGill University Health Centre
- Misericordia Hospital (Winnipeg)
- Mount Sinai Hospital (Toronto)
- Royal Alexandra Hospital (Edmonton)
- Royal University Hospital (Saskatoon)
- St. Boniface Hospital
St. Joseph’s Healthcare Hamilton
St. Michael’s Hospital (Toronto)
St. Paul’s Hospital (Vancouver)
Stollery Children’s Hospital (Edmonton)
Sturgeon Community Hospital (Alberta)
The Hospital for Sick Children (Toronto)
University of Alberta Hospital
Vancouver General Hospital
Winnipeg Health Sciences Centre
Women’s Health Concerns Clinic (Hamilton)

Industry: 24
AIM Therapeutics
Allergic Living Magazine
Altair Therapeutics
Asmacure
AstraZeneca Canada Inc.
BioDiscovery Inc.
Chenomx
Fisher Scientific
Genentech Inc.
Gennum Corporation
GlaxoSmithKline Inc.
Graham Scott Strategies Inc.
King Pharma
Leap Learning Technologies
Longwoods Publishing
Lumira Capital Corporation
Mark Bisby Consultants
Merck Frosst Canada
Novartis Pharmaceuticals Canada Inc.
Schering-Plough Canada Inc.
Sedulous Investments
Sporometrics Inc.
TEC Edmonton
Wyeth Pharmaceuticals Inc.

Federal Agencies: 9
Assisted Human Reproduction Canada
Canadian Mortgage and Housing Corporation
Environment Canada
Health Canada, Bureau of Chemical Safety
in the Food Directorate
Health Canada, Air Health Division, Water,
Air and Climate Change Bureau
National Institutes of Arthritis and
Musculoskeletal and Skin Diseases
National Institutes of Health
National Research Council - Biotechnology
Research Institute
Public Health Agency of Canada

Provincial Agencies: 14
Alberta Health Services
Alberta Ministry of Education
Evergreen Catholic Separate Regional School
Division #2 (Alberta)
Fonds de la recherche en santé du Québec
Horizon Health Network (New Brunswick)
The District 18 School Board (New Brunswick)
Kikino Elementary, Northern Lights School
Division No.69 (Alberta)
Louis Riel School Division (Manitoba)
Ontario Ministry of Health and Long-Term Care
Ontario Ministry of Labour
River East Transcona School Division (Manitoba)
St. James School Division (Manitoba)
Winnipeg School Division
Workplace Safety and Insurance Board, Ontario

Research Institutes and Networks: 20
C2OERD - The Lung Centre,
Vancouver General Hospital
Canadian Institute for Advanced Research
The Canadian Research Institute for Social Policy
(CRISP - New Brunswick)
Centre de recherche du Centre hospitalier
de l’Université de Montréal
Child and Family Research Institute, UBC
Firestone Institute for Respiratory Health,
McMaster University
Gage Occupational and Environmental Health Unit,
University of Toronto
Helmholtz Zentrum München,
University of Munich
Institut de Recherche Robert-Sauvé en
Santé et en Sécurité du Travail, Québec
Institute for Clinical Evaluative Sciences (ICES)
International Science and Technology
Partnerships Canada
James Hogg iCAPTURE Centre, UBC
Karolinska Institute (Sweden)
Occupational Allergy Interest Group of European Academy of Allergy and Clinical Immunology
Robarts Research Institute,
University of Western Ontario
Southern Ontario Centre for Atmospheric Aerosol Research
St. John’s Research Institute (India)
The UBC Centre for Health and Environment Research
U.S. Environmental Protection Agency
Uvic Genome BC Proteomics Centre,
University of Victoria

Associations/Foundations/
Other Bodies: 45
Alberta ACADRE-NEAHR Network
Alberta Asthma Centre
Alberta Heritage Foundation for Medical Research
Alberta Strategy to help Manage Asthma & COPD (ASTHMA C)
Allergy Asthma Information Association (AAIA)
Allergy, Asthma Information Association (Prairies, NWT, Nunavut & Atlantic Division)
Alexander Von Humboldt Foundation (Germany)
The Allergy and Environmental Health Association of New Brunswick
American Thoracic Society
Anaphylaxis Canada
Association québécoise des allergies alimentaires (AQAA)
Asthma Society of Canada
BC Lung Association
Burroughs Wellcome Fund
Canadian Allergy Asthma and Immunology Foundation (CAAIF)
Canadian Child Health Clinician Scientist Program
Canadian Cystic Fibrosis Foundation
Canadian Lung Association
Canadian Medical Protective Association
Canadian Society of Asthma and Clinical Immunology
Canadian Thoracic Society
Centre for Asthma in the Workplace
Centre for Research Expertise in Occupational Disease
Childhood Asthma Foundation
Children’s Hospital Foundation of Manitoba
Chongqing Biomedical Engineering Society (China)
Imperial College of London, GABRIEL Project
Global Allergy and Asthma European Network (GA²LEN)
Hamilton Community Foundation
International Union Against Tuberculosis and Lung Disease
Ireland Canada University Foundation
The Lung Association, Alberta & NWT
Lung Association of Nova Scotia
Manitoba ACADRE-NEAHR Network
Michael Smith Foundation for Health Research
Multiple Sclerosis Society of Canada
National Collaborating Centre for Environmental Health
National Sanitarian Association
Nova Scotia ACADRE-NEAHR Network
Nurse Practitioners’ Association of Ontario
Ontario Lung Association
Respiratory Global Research And Training Network
St. Joseph’s Immigrant Women’s Centre (Hamilton)
The COPD and Asthma Network of Alberta
World Health Organization – Global Alliance against chronic Respiratory Disease (GARD)
AllerGen’s national network fully embraced the IPI program with 55 investigators collaborating internationally, representing 41% of AllerGen’s researchers.
Knowledge and Technology Exchange and Exploitation (KTEE)

**AllerGen is committed to KTEE and continually endeavours** to find meaningful and unique channels to commercialize, engage, inform and share knowledge arising from Network research undertaken with partners and stakeholders including not-for-profit asthma, allergy and related immune disease organizations, clinicians and healthcare professionals, asthma educators, the general public, policy makers and other decision makers.

An effective KTEE strategy is critical to successfully disseminating Network research results and ensuring that the social and economic value of AllerGen’s national and international initiatives are realized. AllerGen is committed to KTEE and has invested in a wide range of initiatives to commercialize, engage, inform and share knowledge arising from Network research undertaken with partners and stakeholders including not-for-profit asthma, allergy and related immune disease organizations, clinicians and healthcare professionals, asthma educators, the general public, policy makers and other decision-makers.

**AllerGen’s International Partnership Initiative (IPI)**

As a highly integrated, multi-disciplinary and multi-sectoral national research network, AllerGen has established strong ties with international organizations and academic institutions. This has been possible through AllerGen’s successful implementation of an IPI program.

AllerGen’s national network fully embraced the IPI program with 55 investigators collaborating internationally, representing 41% of AllerGen’s researchers.

**Highlights from AllerGen’s 2009-2010 IPI collaborations:**

Significant developments continued to emerge from AllerGen’s partnership with the International Union Against Tuberculosis and Lung Disease (The Union) in El Salvador led by AllerGen investigator Dr. Dean Befus and asthma educator and allergy and research collaborator, Shawna McGhan, both from the University of Alberta. In April 2009, development and planning of resources and services, including the structure and activities of the asthma clinic, community-based resources and teaching tools relevant for use in El Salvador, were completed. A press release was developed in Edmonton and picked up by the media, highlighting the partnership and related plans. Canadian teams revisited El Salvador in January and March 2010 where major milestones were achieved — the signing of a Memorandum of Understanding, and presentation of the “Asthma Action Plan” adapted from the Alberta Asthma...
Action Plan and “My Asthma Calendar.” The El Salvadorian “Asthma Teaching Flip Chart” was also presented in draft form and strategies for its use were explored. A firm commitment, next steps and partnership approach were defined between the University of Alberta, The Union and the Ministry of Health for a country-wide rollout of the asthma program, a management pilot and an Asthma Drug Facility in El Salvador.

AllerGen’s partnership with the Global Asthma and Allergy European Network (GA2LEN) has positioned AllerGen investigators in a leadership position with respect to genome-wide association studies of asthma and allergy. Relationships developed through the GA2LEN partnership are leveraging future opportunities for AllerGen. A meeting was held at the Collegium Internationale Allergologicum Symposium held in Ischia, Italy in April 2010 concerning further advancement of the GABRIEL collaboration.

In November 2009, AllerGen investigators participated in meetings in Sweden with collaborators from the Karolinska Institute and representatives of the Institute of Epidemiology of the Helmholtz Zentrum München. Presentations were delivered on “Traffic-related air pollution relating to infant bronchiolitis and childhood asthma” and “Harmonizing gene and environment data: TRAP’s association with incident asthma, as mediated by oxidative stress.”

Following the meetings in Sweden, trainee and investigator exchanges evolved with the University of British Columbia. Two representatives from the Karolinska Institute met with AllerGen investigators to discuss traffic-related air pollution as a risk factor for the development of childhood asthma (TAG) project. A half-day graduate student symposium was held, allowing a trainee from the Karolinska Institute and seven University of British Columbia graduate students working on air pollution and health research to share research protocols and findings.

AllerGen and St. John’s Research Institute, Bangalore, India held a productive workshop at the AllerGen Annual Research Conference in Quebec City in 2010. The team is now developing an application to the Grand Challenges Canada program to obtain additional funding. This would
enable continuation of their groundbreaking research collaboration, and expand the capacity of their comparative findings about nutritional impacts on the development of chronic diseases, linking malnutrition and obesity to allergy, asthma and diabetes in childhood.

The Respiratory Global Research And Training (GReAT) Network, which fills a knowledge gap by providing training about respiratory disease surveillance by collecting, processing and analyzing national and global data to identify trends, gaps and solutions to improve respiratory care and reduce the related burden of illness on individuals, families, and society, has been another valuable outcome of the IPI program. An e-learning program was developed and conducted via the internet using videoconferencing and desktop-sharing software. Eight international trainees: two students from Pakistan, one from India, two from Brazil, one from Dubai, one from Syria, and one from Thailand, registered and completed the 2009/2010 program. Trainees are working on submitting abstracts to local conferences and preparing research papers for consideration by peer-reviewed journals.

AllerGen in the Media
Sharing AllerGen successes
AllerGen achieved a high level of media coverage throughout 2009-2010.

<table>
<thead>
<tr>
<th>Print</th>
<th>Broadcast</th>
<th>Web/Newsletter</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009-2010</td>
<td>21</td>
<td>7</td>
</tr>
<tr>
<td>All years</td>
<td>157</td>
<td>30</td>
</tr>
</tbody>
</table>

AllerGen in the Media

AllerGen researchers produced 80 refereed publications from April 2009 to March 2010. The total of all publications, ( refereed, non-refereed and specialized) for the 2009-2010 fiscal year was 286, an increase of 86% over the 154 total publications produced during fiscal year 2008-2009.

Global Alliance against chronic Respiratory Diseases (GARD) Annual Conference
Drs Teresa To, Louis Philippe Boulet and Diana Royce provided international leadership on behalf of AllerGen at the 2010 annual GARD-WHO conference held in Toronto, Ontario in June. Dr. Louis-Philippe Boulet participated as an invited speaker on the topic of “Patient Education,” and Dr. To was the official presenter on surveillance, as well as the nominated chair and rapporteur of a working group that focused on “Primary Prevention of Chronic Respiratory Disease.”

AllerGen representatives took part in a working group on care gaps and strengthening capacity for integrated prevention and control of non-communicable diseases in primary care and primary prevention of respiratory diseases. This collaboration with GARD-WHO has raised the profile of AllerGen and facilitated the establishment of international collaborations, particularly in the field of education and prevention.

Ontario Asthma Plan of Action Forum
AllerGen’s Managing Director, Diana Royce, attended the Ontario Asthma Plan of Action Forum in Toronto, Ontario on 27 January 2010. Dr. Royce delivered a presentation on AllerGen’s KT tool, Knowledge Translation Planning Tools for Allergic Disease Researchers, and distributed copies to all attendees.

American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting
AllerGen was represented by several researchers and trainees at the AAAAI meeting in New Orleans, February 26 – March 2, 2010.
European Academy of Allergology and Clinical Immunology (EAACI) Conference
AllerGen researchers attended the prestigious and world-renowned EAACI conference held in Warsaw, Poland from 6-10, June 2009. The conference, Allergy and Asthma without Frontiers, attracted over 6100 delegates and featured over 300 presenters from 42 countries.

The conference also provided AllerGen investigator, Dr. PJ Subbarao, Deputy Director of the CHILD Study, an opportunity to attend a GA2LEN meeting that took place at the conference.

The Canadian Society for Allergy and Clinical Immunology (CSACI) Annual Scientific Meeting
The CSACI Meeting was held in Halifax, Nova Scotia, 22-25, October 2009. AllerGen was well represented with investigators Drs Dean Befus, Susan Waserman, Anne Ellis, Allan Becker, Micheal Kobor, Zave Chad and Managing Director, Dr. Diana Royce in attendance. Dr. Susan Waserman presented on “A New Initiative in Immunotherapy Training;” Dr. Allan Becker delivered a presentation on “Asthma in the Pre-School Child: A rose by any other name?;” Dr. Dean Befus discussed “Novel Pathways in the Neuro-Regulation of Allergic Asthma: “Challenges in Translational Research;” and Dr. Michael Kobor explored “Epigenetic Control of Gene Expression on the Effects of Stress in Asthma.”

Policy, Ethics, Law and Society (PELS) Committee
AllerGen’s PELS Committee is a standing advisory committee reporting to AllerGen’s Research Management Committee (RMC). PELS was established in 2009 to support infrastructure and advice for building bridges between researchers and decision-makers across levels and sectors, including government. PELS advises and supports the RMC in facilitating the translation of AllerGen research that has clinical, policy, ethical, and social implications, identifies emerging issues that warrant a response from the Canadian allergic and immune disease research community, and facilitates the establishment of enduring links amongst AllerGen researchers and Canadian clinicians and policymakers.

On 8 February, 2010, the Chair of the AllerGen PELS Advisory Committee, Tim Caulfield, of the University of Alberta, hosted a policy workshop in Quebec City, Quebec during the annual AllerGen Innovation from Cell to Society research conference. Holding this workshop during the annual conference facilitated the participation of a wide range of policy practitioners and thought leaders from government, patient-based organizations and healthcare as well as leading research scientists from universities across Canada.

The workshop was attended by 18 participants from across five sectors representing clinicians, clinician-scientists, policy makers, non-profit organizations, patient advocates and researchers.

Strategic and operational priorities were identified for the PELS Committee to 31 March 2012 as well as the identification and selection of important policy issues within the scope of AllerGen’s mandate around which it could generate evidence-based statements.

Priority themes for policy statements identified for the PELS Committee were:

i. Diagnosis
ii. Risk perception
iii. Policy responses
iv. Economic impact of allergic disease and implications for workplaces and industry
v. Increasing awareness of allergic disease and the associated risks.
Network-wide Ethics and AllerGen Investigators’ Workshops

Workshop participants explored the framework of research ethics in Canada, the challenges of multi-site research, ethical aspects of international research, research with marginalized populations, and on-going Canada-wide ethics challenges such as studies involving minors, minimizing risk to research participants, and consent issues in research and law.

The three-day ethics workshop not only fostered continued dissemination and exploration within the AllerGen network, but following the workshop, Tim Caulfield, of the University of Alberta utilized information that was shared at the workshop to inform a research article, Handling ethical, legal and social issues in birth cohort studies involving genetic research: responses from studies in six countries, published in BMC Medical Ethics 2010, 11:4 (23 March 2010).

An AllerGen Investigators’ Workshop held on 16 & 18, December 2009, attracted over 60 participants and afforded attendees the opportunity to hear updates on AllerGen’s Integrated Research Programme. Presentations were delivered by 19 AllerGen-funded investigators on their new research initiatives and anticipated outcomes and impacts.

Evidence, Ethics and Health Policy Research Survey
An Evidence, Ethics and Health Policy Research Survey was designed and distributed at AllerGen’s Fifth Annual Research Conference. The goal of the survey was to gather information about perceptions of media representation of allergy/asthma issues, policy and research, and its impact on policy development, funding decisions, public opinion and the use of and need for KT tools.

Significant findings arriving from survey results were that the majority of respondents (70.8%) felt that media representations of allergy/asthma issues, policy and research were accurate. Media representations of allergy/asthma issues, policy and research were also seen to impact health and research policy development (62.5%), impact funding decisions (54.2%) and impact public opinion and understanding (85.4%). The majority of respondents (n=28) shared the view that media representations of allergy/asthma issues, and related policy and research had made them think about their work in a different way.

Lack of resources and policy barriers were identified as the top two challenges facing effective KT and over half of the respondents (56.8%) felt that KT was a very important part of their research program.

Results from this survey will inform the PELS Committee moving forward regarding media representation of allergy/asthma issues, policy and research, policy development, funding decisions and the use of and need for KT tools.
**Tomorrow’s Leaders: AllerGen’s Highly Qualified Personnel**

AllerGen’s Goal: To create new opportunities for the training of HQP in allergy research, patient care, innovation and the health system, and advance professional and lay knowledge about allergic and related immune diseases.

In 2009-2010 AllerGen’s investments led to unique training, leadership, management and skills development opportunities for students and new professionals, educators and clinicians across Canada. AllerGen trainees are being exposed to and integrated into a national and international network of academic, clinical, private sector, public policy and patient advocacy leaders in the field. These opportunities are preparing the next generation to lead social, healthcare and economic advancements in the field of allergy and related immune disease.

**AllerGen Fellowships and Awards**

- AllerGen’s Canadian Allergy and Immune Diseases Advanced Training Initiative (CAIDATI) awards provide new training opportunities for undergraduate summer students and students pursuing MD, Masters and PhD degrees and post-doctoral fellows specializing in research relevant to biomedical, health, social and/or natural science and engineering research about allergy, asthma and related immune/inflammatory processes and disease. The following are a list of recipients of AllerGen’s CAIDATI awards:
  - Katherine Arias, PhD, *The contribution of distinct immunological pathways leading...*
to peanut induced anaphylaxis (PIA), McMaster University

- Svetlana Carrigan, MD, PhD, Post-Doctoral Fellow, *Mechanisms and regulations of IgE-dependent mast cell activation in allergy*, Dalhousie University

- Kathleen Fraser, MSc, *Assessing the regulatory capacity of dendritic cells as a marker of atopy in cord blood*, Queen’s University

- Marie-Hélène Lambert, MSc, *Gene-Gene Interaction for CX3CR1 in asthma*, Université du Québec à Chicoutimi

- Julie Schmied, PhD, *Prophylaxis of food allergy by defined bacterial component pre-treatments in a neonatal swine model of allergy*, University of Guelph

- Elinor Simons, PhD, *The longitudinal impact of environmental exposures on the development of childhood atopy*, University of Toronto

- Christopher Skappak, PhD, *The metabolomic analysis of respiratory virus infection in an asthma model via Nuclear Magnetic Resonance (NMR) spectroscopy*, University of Alberta

- Christopher Taplin, MSc, *Epigenetic profiling of bronchial epithelial cells*, University of British Columbia

- Stephanie Warner, PhD, *P63 regulates differentiation and adhesion of human airway epithelial cells: Implications for airway remodelling in asthma*, University of British Columbia

- The CTS/CLA/AllerGen Clinician Scientist Research Fellowship, valued at $115,000 over a two year period, is provided to increase capacity to conduct world class asthma, allergy and immune disease research in Canada. The recipient of this fellowship was Brandie Walker, University of Calgary.

**AllerGen Travel Awards**

In 2009-2010 AllerGen provided 40 trainees with travel awards to accelerate their professional development. Through the AllerGen Travel Award Programme, AllerGen matches partner contributions to cover the travel and accommodation

AllerGen trainees left to right: Mathieu Cooney, Henry Huang, Jing Luo with Allan Becker
costs of AllerGen investigators and HQP attending events (meetings, symposiums and conferences, etc.) outside of AllerGen that will contribute to their professional development.

These events must align with AllerGen’s mission, values and goals and provide new opportunities for networking, research collaboration, knowledge translation, skill development and learning.

- Steven Maltby, PhD student at the University of British Columbia and Steven Smith, PhD student at McMaster University were selected to present their work at the Sixth Biennial Symposium of the International Eosinophil Society in Bruges, Belgium.
- Five AllerGen trainees, Nivedita Khanna, Post-Doctoral Fellow at the University of Toronto, Michelle North, PhD student at the University of Toronto, Gurpreet Singhera, PhD student at the University of British Columbia, Mary Speck, a Research Technician at the University of Toronto and Bruce Urch, PhD student at the University of Toronto attended the American Thoracic Society International Conference in San Diego, California. The conference offered more than 400 sessions and 800 speakers focused on important scientific and clinical advances in adult and pediatric respiratory medicine.
- Six AllerGen trainees attended the American Academy of Asthma, Allergy and Immunology (AAAAI) in New Orleans, Louisiana including, Adrian Baatjes, PhD student at McMaster University, Irene Fung, MD student at McMaster University, Delia Heroux, Research Technician at McMaster University, Pia-Lauren Reece, PhD student at McMaster University, Kristin Weiße, a Post-Doctoral Fellow at McMaster University on exchange from the Helmholtz Centre for Environmental Research, Leipzig, Germany and Sophia Xu, a PhD student at McMaster University.
- Jennifer Protudjer, PhD student at the University of Manitoba was selected to present her work at the International Congress on Obesity at The Karolinska Institute in Stockholm, Sweden.
AllerGen Annual Conference
Student Poster Competition
AllerGen’s Fifth Annual Research Conference took place in Québec City from February 7-9, 2010. Sixty-three trainees from nine universities – Simon Fraser University, University of British Columbia, McMaster University, McGill University, University of Toronto, Queen’s University, Laval University, University of Manitoba and University of Alberta — attended the conference.

The Student Poster Competition took place during the first two days of the conference and the posters were on display and viewed by the poster judges and conference attendees. AllerGen received a record number of 51 high quality abstract submissions. There were 7 in Gene-Environment Interactions (Programme A), 23 in Diagnostics and Therapeutics (Programme B), 10 in Public Health, Ethics, Policy and Society (Programme C) and 11 non-adjudicated posters. Six trainees (two per AllerGen Research Programme area), Programme A: Salman Ali, University of British Columbia and Michelle North, University of Toronto; Programme B: Steven Maltby, University of British Columbia and Ramses Ilarraza, University of Alberta; Programme C: Salma Bahreinian, University of Alberta, and Daniel Harrington, McMaster University, were judged to be the highest scoring candidates and presented their abstracts to the conference in the form of oral presentations.

The Student Poster Competition allows AllerGen’s students to share their research, to exchange ideas and to network with other trainees and researchers, clinicians, policy and decision makers, health care administrators and representatives from business, industry and government.

AllerGen Annual Trainee Symposium
In 2009, the AllerGen Students and New Professionals Network (ASNPN) held its Fourth Annual AllerGen Trainee Symposium, in Montréal, Québec. The theme of the 2009 symposium was Becoming Future Leaders: Challenges and Successes. Speakers included:

- Dr. Jacob Kraicer, Resident Scholar, Department of Physiology, Faculty of Medicine, University of Toronto (author of The Art of Grantsmanship)
The symposium provided an excellent opportunity for trainees and new professionals to network and discuss their multi-disciplinary projects. The program included the following sessions:

- Effective grant writing: funding agency and researcher perspectives;
- Dissemination of research and knowledge translation;
- Career panel: Small Biotech, Big Pharma and Government Perspectives;
- Mentoring and teaching: Supervisor-Trainee Relationship & Mentoring Junior Trainees;
- Transitioning to the “real world;” and
- Half-day interactive workshop: An Introduction to Presentation Skills.

**Network Graduates**

In 2009-2010, 19 trainees graduated from the Network and are working in government, industry,
academic institutions and the public sector. Specifically:

Scott Weichenthal, a former McGill University PhD student under the supervision of Dr. Claire Infant-Rivard, is now working in the Exposure Assessment Section, Air Health Effects Division, Water, Air and Climate Change Bureau of Health Canada.

Ilan Asher, a former McMaster University post-doctoral fellow, under the supervision of Dr. Judah Denburg, completed his international fellowship and has returned to Israel where he is a practicing clinician.

Marie-Renée Blanchet, a former University of British Columbia post-doctoral fellow, under the supervision of Dr. Kelly McNagny, has completed her training and has secured a tenure track position at Laval University and is a Principal Investigator on an AllerGen project.

**AllerGen Students and New Professionals**

The total number of AllerGen trainees in the Network is 396. The remaining 78 HQP not illustrated on the chart below represent the students and new professionals not working on Network research but who remain active members of the ASNPN. The AllerGen ASNPN provides significant “hands-on” opportunities for trainees and new professionals to develop their own leadership, management, administrative, event planning and communications skills. In addition, the ASNPN provides strategic advice to the Advanced Education and Training Opportunities Advisory Committee (AETOAC) on AllerGen’s HQP programme priorities and tactics.

**Number of HQP Working on Network Research by Year**

2009-2010 Number of HQP Working on Network Research (N=318)

<table>
<thead>
<tr>
<th>Year</th>
<th>Undergrad</th>
<th>MD</th>
<th>Masters</th>
<th>PhD</th>
<th>PDF</th>
<th>Research Associates/ Technicians</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005-2006</td>
<td>11</td>
<td>12</td>
<td>28</td>
<td>31</td>
<td>37</td>
<td>52</td>
</tr>
<tr>
<td>2006-2007</td>
<td>14</td>
<td>14</td>
<td>46</td>
<td>57</td>
<td>43</td>
<td>71</td>
</tr>
<tr>
<td>2007-2008</td>
<td>12</td>
<td>12</td>
<td>37</td>
<td>30</td>
<td>43</td>
<td>71</td>
</tr>
<tr>
<td>2008-2009</td>
<td>11</td>
<td>11</td>
<td>28</td>
<td>28</td>
<td>43</td>
<td>57</td>
</tr>
<tr>
<td>2009-2010</td>
<td>11</td>
<td>11</td>
<td>28</td>
<td>28</td>
<td>43</td>
<td>57</td>
</tr>
</tbody>
</table>
AllerGen trainees are being exposed to and integrated into the national and international network of academic, clinical, private sector, public policy and patient advocacy leaders in the field. These opportunities are preparing the next generation to lead social, healthcare and economic advancements in the area of allergy and related immune disease.
## Financial Overview

### AllerGen NCE Inc. Financial Overview 2009-2010

<table>
<thead>
<tr>
<th>Revenues</th>
<th>2008-09 (Year 4)</th>
<th>Percentage</th>
<th>2009-2010 (Year 5)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCE Award</td>
<td>5,306,000</td>
<td>26.7%</td>
<td>5,216,500</td>
<td>29.6%</td>
</tr>
<tr>
<td>IDRC Award - St. John’s Institute, Bangalore, India</td>
<td>110,400</td>
<td>0.6%</td>
<td>-</td>
<td>0.0%</td>
</tr>
<tr>
<td>Non-NCE Funds to Administrative Centre*</td>
<td>1,006,242</td>
<td>5.1%</td>
<td>587,183</td>
<td>3.3%</td>
</tr>
<tr>
<td>Non-NCE Funds To Research *</td>
<td>13,484,575</td>
<td>67.7%</td>
<td>11,809,790</td>
<td>67.0%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>19,907,217</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>17,613,474</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenditures (Cash)</th>
<th>2008-09 (Year 4)</th>
<th>Percentage</th>
<th>2009-2010 (Year 5)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Programs</td>
<td>3,244,679</td>
<td>64.1%</td>
<td>4,661,638</td>
<td>71.5%</td>
</tr>
<tr>
<td>Networking</td>
<td>592,531</td>
<td>11.7%</td>
<td>552,680</td>
<td>8.5%</td>
</tr>
<tr>
<td>Strategic Initiatives and Training</td>
<td>242,374</td>
<td>4.8%</td>
<td>222,173</td>
<td>3.4%</td>
</tr>
<tr>
<td>Communications</td>
<td>15,161</td>
<td>0.3%</td>
<td>14,461</td>
<td>0.2%</td>
</tr>
<tr>
<td>Administration</td>
<td>964,988</td>
<td>19.1%</td>
<td>1,069,159</td>
<td>16.4%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>5,059,733</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>6,520,111</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Committed Amounts for Future research</th>
<th>2008-09 (Year 4)</th>
<th>Percentage</th>
<th>2009-2010 (Year 5)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash reserves</td>
<td>3,496,326</td>
<td>-</td>
<td>3,305,582</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>1,569,228</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>1,294,582</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

### Revenue Sources (Cash and In-Kind) 2009/10

<table>
<thead>
<tr>
<th>Source</th>
<th>Cash</th>
<th>In-Kind</th>
<th>Total</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCE</td>
<td>5,216,500</td>
<td>-</td>
<td>5,216,500</td>
<td>29.6%</td>
</tr>
<tr>
<td>Industry</td>
<td>2,617,566</td>
<td>271,650</td>
<td>2,889,216</td>
<td>16.4%</td>
</tr>
<tr>
<td>University</td>
<td>1,807,799</td>
<td>2,669,331</td>
<td>4,477,130</td>
<td>25.4%</td>
</tr>
<tr>
<td>Other Sources</td>
<td>628,572</td>
<td>497,658</td>
<td>1,126,230</td>
<td>6.4%</td>
</tr>
<tr>
<td>Hospital</td>
<td>844,223</td>
<td>641,725</td>
<td>1,485,948</td>
<td>8.4%</td>
</tr>
<tr>
<td>Federal</td>
<td>902,226</td>
<td>335,705</td>
<td>1,237,931</td>
<td>7.0%</td>
</tr>
<tr>
<td>Not-for-Profit</td>
<td>750,795</td>
<td>289,223</td>
<td>1,040,018</td>
<td>5.9%</td>
</tr>
<tr>
<td>Provincial</td>
<td>110,000</td>
<td>30,500</td>
<td>140,500</td>
<td>0.8%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>12,877,682</strong></td>
<td><strong>4,735,792</strong></td>
<td><strong>17,613,474</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

* Includes cash and in-kind contributions
## Network Participants 2009-2010

<table>
<thead>
<tr>
<th>Researchers</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Seifert</td>
<td>Agriculture &amp; Agri-Food Canada</td>
</tr>
<tr>
<td>Mary Allen</td>
<td>Allergy Asthma Information Association</td>
</tr>
<tr>
<td>Matthew Nisbet</td>
<td>American University</td>
</tr>
<tr>
<td>Marilyn Allen</td>
<td>Anaphylaxis Canada</td>
</tr>
<tr>
<td>Laurie Harada</td>
<td>Anaphylaxis Canada</td>
</tr>
<tr>
<td>Claire Dufresne</td>
<td>Association québécoise des allergies alimentaires</td>
</tr>
<tr>
<td>Christine Hampson</td>
<td>Asthma Society of Canada</td>
</tr>
<tr>
<td>Wendy Untereiner</td>
<td>Brandon University</td>
</tr>
<tr>
<td>David Scheifele</td>
<td>British Columbia Children’s Hospital</td>
</tr>
<tr>
<td>Francine Deschesnes</td>
<td>Centre hospitalier de l'Université Laval</td>
</tr>
<tr>
<td>Maike Pincus</td>
<td>Charité-University Medicine Berlin</td>
</tr>
<tr>
<td>Ulrich Wahn</td>
<td>Charité-University Medicine Berlin</td>
</tr>
<tr>
<td>Tong-Jun Lin</td>
<td>Dalhousie University</td>
</tr>
<tr>
<td>Jean Marshall</td>
<td>Dalhousie University</td>
</tr>
<tr>
<td>Susan Sherwin</td>
<td>Dalhousie University</td>
</tr>
<tr>
<td>Wade Watson</td>
<td>Dalhousie University</td>
</tr>
<tr>
<td>Jeffrey Brook</td>
<td>Environment Canada</td>
</tr>
<tr>
<td>Marjan Kerkhof</td>
<td>Groningen University</td>
</tr>
<tr>
<td>Gerard Koppelman</td>
<td>Groningen University</td>
</tr>
<tr>
<td>Salim Yusuf</td>
<td>Hamilton General Hospital/McMaster University</td>
</tr>
<tr>
<td>Diane Gold</td>
<td>Harvard University</td>
</tr>
<tr>
<td>Petros Koutrakis</td>
<td>Harvard University</td>
</tr>
<tr>
<td>Sheila Dubois</td>
<td>Health Canada</td>
</tr>
<tr>
<td>Samuel Godefrey</td>
<td>Health Canada</td>
</tr>
<tr>
<td>Ling Liu</td>
<td>Health Canada</td>
</tr>
<tr>
<td>John Salminen</td>
<td>Health Canada</td>
</tr>
<tr>
<td>Hari Vijay</td>
<td>Health Canada</td>
</tr>
<tr>
<td>Éric Meslin</td>
<td>Indiana University</td>
</tr>
<tr>
<td>Gianna Moscato</td>
<td>Instituto Scientifico di Pavia</td>
</tr>
<tr>
<td>Göran Pershagen</td>
<td>Karolinska Institutet</td>
</tr>
<tr>
<td>Barbro Dahlén</td>
<td>Karolinska Institutet</td>
</tr>
<tr>
<td>Sven-Erik Dahlén</td>
<td>Karolinska Institutet</td>
</tr>
<tr>
<td>Janice Minard</td>
<td>Kingston General Hospital</td>
</tr>
<tr>
<td>Jennifer Olajos-Clow</td>
<td>Kingston General Hospital</td>
</tr>
<tr>
<td>Qutayba Hamid</td>
<td>McGill University</td>
</tr>
<tr>
<td>Claire Infante-Rivard</td>
<td>McGill University</td>
</tr>
<tr>
<td>James Martin</td>
<td>McGill University</td>
</tr>
<tr>
<td>Bruce Mazer</td>
<td>McGill University</td>
</tr>
<tr>
<td>Reza Alizadehfar</td>
<td>McGill University Health Centre</td>
</tr>
<tr>
<td>Ann Clarke</td>
<td>McGill University Health Centre</td>
</tr>
<tr>
<td>Lawrence Joseph</td>
<td>McGill University Health Centre</td>
</tr>
<tr>
<td>Faiqe Kaplan</td>
<td>McGill University Health Centre</td>
</tr>
<tr>
<td>Marie-Noël Primeau</td>
<td>McGill University Health Centre</td>
</tr>
<tr>
<td>Petra Arck</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Stephanie Atkinson</td>
<td>McMaster University</td>
</tr>
<tr>
<td>John Bienenstock</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Lisa Colizza</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Michael Cyr</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Judah Denburg</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Paul Forsythe</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Andreas Freitag</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Jack Gauldie</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Gail Gauvreau</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Ted Haines</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Geoffrey Hall</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Mark Inman</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Manel Jordana</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Paul Keith</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Tulay Koru-Sengul</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Mark Larché</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Anthony Levinson</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Kathy McCoy</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Ann McKibben</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Margaret McKinnon</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Parameswaran Nair</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Paul O’Byrne</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Malcolm Sears</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Roma Sehmi</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Claudia Soares</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Martin Stämpfli</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Koon Teo</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Susan Waseeman</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Zhou Xing</td>
<td>McMaster University</td>
</tr>
<tr>
<td>Francine Ducharme</td>
<td>Montreal Children’s Hospital</td>
</tr>
<tr>
<td>Shashank Sheth</td>
<td>Montreal General Hospital</td>
</tr>
<tr>
<td>Noe Zamel</td>
<td>Mount Sinai Hospital, Toronto</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------------------------------------------</td>
</tr>
<tr>
<td>Scott Sicherer</td>
<td>Mount Sinai School of Medicine</td>
</tr>
<tr>
<td>Juan Rivera</td>
<td>National Institutes of Health (USA)</td>
</tr>
<tr>
<td>Janice Butler</td>
<td>Newfoundland and Labrador Centre for Health Research</td>
</tr>
<tr>
<td>Rhoda Kagan</td>
<td>North York General Hospital</td>
</tr>
<tr>
<td>Stacey Ritz</td>
<td>Northern Ontario School of Medicine</td>
</tr>
<tr>
<td>Zacharias Suntres</td>
<td>Northern Ontario School of Medicine</td>
</tr>
<tr>
<td>Jane Kaye</td>
<td>Oxford University</td>
</tr>
<tr>
<td>Cindy Nakatsu</td>
<td>Purdue University</td>
</tr>
<tr>
<td>Roger Deeley</td>
<td>Queen's University</td>
</tr>
<tr>
<td>Diane Lougheed</td>
<td>Queen's University</td>
</tr>
<tr>
<td>John McCans</td>
<td>Queen's University</td>
</tr>
<tr>
<td>Jodan Ratz</td>
<td>Queen's University</td>
</tr>
<tr>
<td>Ryan Allen</td>
<td>Simon Fraser University</td>
</tr>
<tr>
<td>Tim Takaro</td>
<td>Simon Fraser University</td>
</tr>
<tr>
<td>Alan James</td>
<td>Sir Charles Gairdner Hospital, Western Australia</td>
</tr>
<tr>
<td>Bill Musk</td>
<td>Sir Charles Gairdner Hospital, Western Australia</td>
</tr>
<tr>
<td>Richard Summerbell</td>
<td>Sporometrics Inc.</td>
</tr>
<tr>
<td>Swarnarekha Bhat</td>
<td>St. John’s Research Institute, India</td>
</tr>
<tr>
<td>George D’Souza</td>
<td>St. John’s Research Institute, India</td>
</tr>
<tr>
<td>Anura Kurpad</td>
<td>St. John’s Research Institute, India</td>
</tr>
<tr>
<td>Sumithra Muthayya</td>
<td>St. John’s Research Institute, India</td>
</tr>
<tr>
<td>John Kenneth Philip</td>
<td>St. John’s Research Institute, India</td>
</tr>
<tr>
<td>Sylvan Rego</td>
<td>St. John’s Research Institute, India</td>
</tr>
<tr>
<td>K Srinivasan</td>
<td>St. John’s Research Institute, India</td>
</tr>
<tr>
<td>Mario Vaz</td>
<td>St. John’s Research Institute, India</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>St. Michael’s Hospital/University of Toronto</td>
</tr>
<tr>
<td>Dorothy Linn Holness</td>
<td>St. Michael’s Hospital/University of Toronto</td>
</tr>
<tr>
<td>Sharon Dell</td>
<td>The Hospital for Sick Children (Toronto)</td>
</tr>
<tr>
<td>Martin Post</td>
<td>The Hospital for Sick Children (Toronto)</td>
</tr>
<tr>
<td>Felix Ratjen</td>
<td>The Hospital for Sick Children (Toronto)</td>
</tr>
<tr>
<td>Padmaja Subbarao</td>
<td>The Hospital for Sick Children (Toronto)</td>
</tr>
<tr>
<td>Teresa To</td>
<td>The Hospital for Sick Children (Toronto)</td>
</tr>
<tr>
<td>Wendy Ungar</td>
<td>The Hospital for Sick Children (Toronto)</td>
</tr>
<tr>
<td>Lucie Blais</td>
<td>Université de Montréal</td>
</tr>
<tr>
<td>Guy Delespessse</td>
<td>Université de Montréal</td>
</tr>
<tr>
<td>Bartha Knopper</td>
<td>Université de Montréal</td>
</tr>
<tr>
<td>Jean-Pierre Lavoie</td>
<td>Université de Montréal</td>
</tr>
<tr>
<td>Jacques Lussier</td>
<td>Université de Montréal</td>
</tr>
<tr>
<td>Catherine Laprise</td>
<td>Université du Québec à Chicoutimi</td>
</tr>
<tr>
<td>Louis-Philippe Boulet</td>
<td>Université Laval</td>
</tr>
<tr>
<td>Jamila Chakir</td>
<td>Université Laval</td>
</tr>
<tr>
<td>Darryl Adamko</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Jeremy Beach</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Dean Befus</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Igor Burstyn</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Lisa Cameron</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Timothy Caulfield</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Nicola Cherry</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Marek Duszyk</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Gary Eitzen</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Warren Finlay</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Philip Halloran</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Paige Lacy</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Piush Mandhane</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Tom Marrie</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Irvin Mayers</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Shawna McGhan</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Devidas Menon</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Susan Moisey</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Redwan Moqbel</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Brian Rowe</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Sirish Shah</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Miriam Stewart</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Brian Sykes</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Timothy Vander Leek</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Dilini Vethanayagam</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>Harissios Vliagoftis</td>
<td>University of Alberta</td>
</tr>
<tr>
<td>John Henderson</td>
<td>University of Bristol</td>
</tr>
<tr>
<td>Rafeef Abugharbieh</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Jehannine Austin</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Tony Bai</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Michael Brauer</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Ryan Brinkman</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Chris Carlsten</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Edith Chen</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>Moira Chen Yeung</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Denise Daly</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Delbert Dorscheid</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Mark FitzGerald</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Richard Hegele</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Darryl Knight</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Michael Kobor</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Tobias Kollmann</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Michael MacDonald</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Carlo Marra</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Jeff Masuda</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Kelly McNagny</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Gregory Miller</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Peter Paré</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Tom Pfeifer</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Andrew Sandford</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Bob Schellenberg</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Chun Seow</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Donald Stark</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Scott Tebbutt</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Stuart Turvey</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Stephan van Eeden</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>William Welch</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Mark Wilkinson</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Ruben Zamar</td>
<td>University of British Columbia</td>
</tr>
<tr>
<td>Robert Cowie</td>
<td>University of Calgary</td>
</tr>
<tr>
<td>Joe Davison</td>
<td>University of Calgary</td>
</tr>
<tr>
<td>Stephen Field</td>
<td>University of Calgary</td>
</tr>
<tr>
<td>Margaret Kelly</td>
<td>University of Calgary</td>
</tr>
<tr>
<td>Paul Kubes</td>
<td>University of Calgary</td>
</tr>
<tr>
<td>Glenda MacQueen</td>
<td>University of Calgary</td>
</tr>
<tr>
<td>Ron Matheson</td>
<td>University of Calgary</td>
</tr>
<tr>
<td>Chris Mody</td>
<td>University of Calgary</td>
</tr>
<tr>
<td>Michael Jarrett</td>
<td>University of California</td>
</tr>
<tr>
<td>Bruce Wilkie</td>
<td>University of Guelph</td>
</tr>
<tr>
<td>Stephanie Ackerman</td>
<td>University of Illinois at Chicago</td>
</tr>
<tr>
<td>Adnan Custovic</td>
<td>University of Manchester</td>
</tr>
<tr>
<td>Allan Becker</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>Andrew Halayko</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>Kent HayGlass</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>Anita Kozyrskyj</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>Brian MacNeil</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>Clare Ramsey</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>Elizabeth Sellers</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>Abdel Soussi Gounni</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>Ganesh Srinivasan</td>
<td>University of Manitoba</td>
</tr>
<tr>
<td>Nicole Letourneau</td>
<td>University of New Brunswick</td>
</tr>
<tr>
<td>Neil Alexis</td>
<td>University of North Carolina at Chapel Hill</td>
</tr>
<tr>
<td>Eric Crighton</td>
<td>University of Ottawa</td>
</tr>
<tr>
<td>Donald Cockcroft</td>
<td>University of Saskatchewan</td>
</tr>
<tr>
<td>John Gordon</td>
<td>University of Saskatchewan</td>
</tr>
<tr>
<td>Margaret Otlowski</td>
<td>University of Tasmania</td>
</tr>
<tr>
<td>Lisa Cicotto</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Hartmut Grasemann</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>D. Linn Holness</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Irena Kudla</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Wendy Lou</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Jeremy Scott</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>James Scott</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Frances Silverman</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Susan Tarlo</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Ross Upshur</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Peter Vadas</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Susan Watt</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>C. Wilson</td>
<td>University of Waterloo</td>
</tr>
<tr>
<td>Susan Elliott</td>
<td>University of Waterloo</td>
</tr>
<tr>
<td>Patrick Holt</td>
<td>University of Western Australia, Telethon Institute of Child Health Research</td>
</tr>
<tr>
<td>Susan Prescott</td>
<td>University of Western Australia, Telethon Institute of Child Health Research</td>
</tr>
<tr>
<td>Peter Sly</td>
<td>University of Western Australia, Telethon Institute of Child Health Research</td>
</tr>
<tr>
<td>Nigel Paterson</td>
<td>University of Western Ontario</td>
</tr>
<tr>
<td>Bert Brunekreef</td>
<td>Utrecht University</td>
</tr>
<tr>
<td>Kevin Mardell</td>
<td>West Elgin Community Health Centre, Ontario</td>
</tr>
<tr>
<td>John Bielby</td>
<td>Western Australia Centre of Pathology and Medicine</td>
</tr>
</tbody>
</table>
Researchers by university

<table>
<thead>
<tr>
<th>University</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon University</td>
<td>1</td>
<td>0.60%</td>
</tr>
<tr>
<td>Dalhousie University</td>
<td>4</td>
<td>2.50%</td>
</tr>
<tr>
<td>McGill University</td>
<td>9</td>
<td>5.70%</td>
</tr>
<tr>
<td>McMaster University</td>
<td>30</td>
<td>19.10%</td>
</tr>
<tr>
<td>Queen’s University</td>
<td>3</td>
<td>1.90%</td>
</tr>
<tr>
<td>Simon Fraser University</td>
<td>2</td>
<td>1.30%</td>
</tr>
<tr>
<td>Université de Montréal</td>
<td>6</td>
<td>3.80%</td>
</tr>
<tr>
<td>Université du Québec à Chicoutimi</td>
<td>1</td>
<td>0.60%</td>
</tr>
<tr>
<td>Université Laval</td>
<td>2</td>
<td>1.30%</td>
</tr>
<tr>
<td>University of Alberta</td>
<td>24</td>
<td>15.30%</td>
</tr>
<tr>
<td>University of British Columbia</td>
<td>31</td>
<td>19.70%</td>
</tr>
<tr>
<td>University of Calgary</td>
<td>6</td>
<td>3.80%</td>
</tr>
<tr>
<td>University of Guelph</td>
<td>1</td>
<td>0.60%</td>
</tr>
<tr>
<td>University of Manitoba</td>
<td>9</td>
<td>5.70%</td>
</tr>
<tr>
<td>University of New Brunswick</td>
<td>1</td>
<td>0.60%</td>
</tr>
<tr>
<td>University of Ottawa</td>
<td>1</td>
<td>0.60%</td>
</tr>
<tr>
<td>University of Saskatchewan</td>
<td>2</td>
<td>1.30%</td>
</tr>
<tr>
<td>University of Toronto</td>
<td>21</td>
<td>13.40%</td>
</tr>
<tr>
<td>University of Waterloo</td>
<td>1</td>
<td>0.60%</td>
</tr>
<tr>
<td>University of Western Ontario</td>
<td>2</td>
<td>1.30%</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>157</td>
<td>100%</td>
</tr>
</tbody>
</table>

International Network collaborators

<table>
<thead>
<tr>
<th>University</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>American University</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>Charité-University Medicine Berlin</td>
<td>2</td>
<td>8.3%</td>
</tr>
<tr>
<td>Groningen University</td>
<td>2</td>
<td>8.3%</td>
</tr>
<tr>
<td>Harvard University</td>
<td>2</td>
<td>8.3%</td>
</tr>
<tr>
<td>Indiana University</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>Mt. Sinai School of Medicine</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>Purdue University</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>University of Bristol</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>University of California</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>University of Manchester</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>University of Illinois at Chicago</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>University of North Carolina at Chapel Hill</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>University of Oxford</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>University of Tasmania</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td>University of Western Australia</td>
<td>6</td>
<td>25.0%</td>
</tr>
<tr>
<td>Utrecht University</td>
<td>1</td>
<td>4.2%</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>24</td>
<td>100%</td>
</tr>
<tr>
<td><strong>Grand Total</strong></td>
<td>181</td>
<td>100%</td>
</tr>
</tbody>
</table>

* Represents all ongoing AllerGen projects as of March 31, 2010.
Nancy Fenton
Kristin Flader
Joe Fragapane
Ian Frankish
Kathleen M. Fraser
Erin Frohwerk
Calvin Fung
Irene Fung
Sylvianne Gagnon
Agustina Gancia-Godoy
Nicole Garzia
Émilie Gélinas-Lymburner
Kim Gilbert
Harpreet Gill
Kulvinder Gill
Ashley Gluchowski
Matt Gold
Pol Gomez
Loie Goronfolah
Karine Guerin Montpetit
Derek Haaland
Tillie-Louise Hackett
Jamie Haddon
Oumnia Hajoui
Christian Harrington
Daniel Harrington
Isabel Hartwig
Yavuz Havluçu
Jianqing He
Heather Henley
Darcy Heron
Jeremy Hirota
Alison Hirukawa
Ryan Hoeve
Jeff Hogan
Shelley Holland
Doug Houlbrook
Hao (Henry) Huang
Michael Hughes
Claudia Hui
Tyler Hynes
Haruki Imaoka
Ramses Illaraza
Yuji Ishimatsu
Alisha Jabar
Caitlin Jago
Nelishah Jiwani
Sarah Kam
Harutai Kamalaporn
Cynthia Kanagaratham
Nala Kandiah
Nitin Kapur
Khalil Karimi
Michael Kariwo
Colleen Keast
Elaine Keung
Ibrahim Khambati
Nivedita Khanna
Katie Killorn
John Dongil Kim
Vy Kim
Linda Kirste
Megan Knoll
Tedd Konya
Marie-Helene Lambert
Émilie Lanctôt-Setlawkwe
Anouk Laviole-Lamoureux
Mathilde Leclère
Jeremy Levi
Ilan Levy
William Li
Yuriy Lissitsyn
Alba Llop-Guevara
Daniela Loefler
Larisa Lotoski
Mark Loewen
Lionel Loubaki
Elaina MacIntyre
Emily Maclean
Stephanie Macpherson
Ruth Macredmond
Randy McDonald
Steven Maltby
David Marchant
Rafael Marino
Andrea Marrin
Nico Marr
Amir Hassaine Massoud
Brianne Miller
Troy Mitchell
Karim Mitha
Katherine Morris
Rabyah Murji
Natalia Mykhaylova
Nha Nguyen Luu
Michelle North
Sharon Oldford
Mostafa Osman
Amanda Ottley
Benjamin Patchell
Angela Paulson
Miki Peer
Cheryl Peters
Sintra Phumethum
Tracy Pitt
Tyler Pittman
Sophie Plante
Giuseppe Pontoriero
David Préfontaine
Jennifer Protudjer
Mandy Pui
Pia Reece
Marcos Ribeiro
Johanna Roa
Natalia Rodrigues
Winnie Sao
Erik Saude
Natalija Saurek-Aleksandrovskaja
Lauren Segal
Charis Segeritz
Shaun Selcer
Pawan Sharma
Heather Sharpe
David Shih
Paris Shosharti
Huan Shu
Elinor Simons
Gurpreet K. Singhera
Dave Sirosis-Gagnon
Christopher Skappak
Steve Smith
Maria Emilia Solano
Lianne Soller
Kristin Stawiarski
Andrew Steer
Dorota Stefanowicz
Guy Tal
Anthony Tang
Christopher Taplin
Amir Tashakkor
Amudhinie Thanendran
Sara Thunberg
Candice Todd
Vanessa Tremblay-Vaillancourt
Candy Tsang
Matthew Tunis
Julie Turmel
Bruce Urch
Rattanjeet Vig
Ava Vila
Cristina Villa-Roel
Thea Van Rossum
Samuel Wadsworth
Hope Walker
Rongrong Wang
Kristin Weiße
Jim Wickware
Lian Willetts
Gabriella Wojewodka
Jungang Xie
Sophia Xu
Lauren Yallop
Howard Yan
Jasemine Yang
Aaron Young
Ricardo Zamel
Caleb C.J. Zavitz
Jian Zhang
Mark Zhou
Steven Zuccarelli
Research Associated and Technicians

Linda Armstrong-Edwards  
Eshetu Atenafu  
Susan Balkovec  
Graham Barr  
Riva Bendit  
Mylène Bertrand  
Agatha Blancas  
Darren Blimkie  
Marie-Eve Boulay  
John Bousfield  
Bing Cai  
Heather Campbell  
Nancy Chase  
Heidi Cheung  
Rishma Chooniedass  
Laura Clark  
Sébastien Claveau  
Miriam Clément  
Lindsey Colley  
Mary Conway  
Marg Coote  
Mahtab Davari  
Pearl Davis  
Wojciech Dawicki  
René Dery  
Francine Deschesnes  
Susan Donnelly  
James Dooley  
Suzanne Dostaler  
Wenming Duan  
Joanne Duncan  
Judy Durocher  
Anne Dybuncio  
Marianne Eduards

Russ Ellis  
Jan Falcone  
Mike Fila  
Alexandra Fok  
Amelie Forget  
Edgardo Fortuno III  
Valerie Garcia  
Brenda Gerwing  
Lucy Gortcon  
Susanna Gontcharova  
Justina Greene  
Leah Greene  
Rajdip Grewal  
Maja Grubisic  
Pampa Guha  
Agnesa Gulich  
Erika Haber  
Anita Hall  
Fay Hart  
Carrie Hartman  
Matthew Hartman  
Ryan Hartman  
Stephanie Harvard  
Michael Henderson  
Delia Heroux  
Aaron Hirschfeld  
Jennifer Hogg  
Karen Howie  
Linda Hui  
Robyn Hyde-Lay  
Kay Jiang  
Brianna Julien  
Ursula Kedala  
Arlene Kallos  
Barbara Karlen  
Tosha Kells  
Amy Kwan  
Erika Ladouceur  
Salma Lalji  
Ann Sofie Lantz  
Sara Leckie  
Louise Lee  
Amanda Lee  
Diana Lefebvre  
Josiane Lefebvre-Lavoie  
Johane Lepage  
Bruce Lix  
Ingrid Loewen  
Angélique Longtin  
Sherry Lu  
Karl Zdravko Lukic  
Jing Luo  
Merideth MacKenzie  
Deborah MacNiel  
Pat MacPherson  
Dennell Mah  
Iqbal Mahabood  
Edward Makwarimba  
Peter Mastrangelo  
Janice Menzies  
Helen Merkens  
Joanne Milot  
Crystal Mitchell  
Hanén M’Kaouar  
Taka Murakami  
Karen Murphy  
Mehdi Najafzadeh  
Sarah Neuman  
Christina Neville  
Erin Nicholls  
Geraldine Nicol  
George Obminski  
Linda O’Connor  
Megan O’Connor  
Popi Panaritis  
Julie Park  
Gabriel Pépin  
Boris Perelman  
Marcelle Petitclerc  
Chandra Pham  
Kerry-Ann Porter  
Philippe Prince  
Christen Rachul  
Sanjay Ramachandran  
Nadia Rampersad  
Shana Regush  
Denise Reid  
Nola Ries  
Isha Rivera  
Roxanne Rousseau  
Jian Ruan  
Heinz Schultz  
Linda Sellery  
Shahjereen Shahidullah  
Mary Speck  
Chris St. Laurent  
Yvan St. Pierre  
Lisa Steacy  
Tara Strinich  
Jasmin Sze  
Jenny Thiele  
Francis Thomai  
Bruce Thong  
Caroline Tremblay  
Ben Tripp  
Elizabeth Turnbull  
Marie-Pierre Viau  
Hélène Villeneuve  
Michelle Vine  
Vicki Waddingham  
Tina Walker  
Terry Walker  
Xiu Yu Wang  
Ruth Warren  
Richard Watson  
Jennifer Wattie  
Kristin Westland  
Rebecca Wickett  
Lesley Wiltshire  
Nathalie Y  
Rossitta Yung  
David Zamar  
Lori Zbytnuik  
Xiaobei Zhang
## Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graham Scott</td>
<td>Chairman of the Board; CEO, Graham Scott Strategies Inc.</td>
</tr>
<tr>
<td>Claude Roy</td>
<td>Vice-Chairman of the Board; Gastroenterologist and Professor Emeritus, Hôpital Ste-Justine</td>
</tr>
<tr>
<td>Judah Denburg</td>
<td>Scientific Director and CEO, AllerGen NCE Inc.</td>
</tr>
<tr>
<td>Douglas Barber</td>
<td>Distinguished Professor in Residence, Faculty of Engineering, McMaster University</td>
</tr>
<tr>
<td>Howard Bergman</td>
<td>Vice-President and Scientific Director, Fonds de la recherche en santé du Québec</td>
</tr>
<tr>
<td>Mark Bisby</td>
<td>Consultant</td>
</tr>
<tr>
<td>Zave Chad</td>
<td>Allergist and Clinical Immunologist</td>
</tr>
<tr>
<td>Deborah Danoff</td>
<td>Adjunct Professor, Department of Medicine, University of Ottawa</td>
</tr>
<tr>
<td>Kevin Fehr</td>
<td>Director, R&amp;D Alliances, GlaxoSmithKline Inc.</td>
</tr>
<tr>
<td>Gail Gauvreau</td>
<td>Associate Professor, McMaster University</td>
</tr>
<tr>
<td>Peter George</td>
<td>President, McMaster University</td>
</tr>
<tr>
<td>Christine Hampson</td>
<td>President and CEO, The Asthma Society of Canada</td>
</tr>
<tr>
<td>Eric Leith</td>
<td>Chair, Canadian Allergy, Asthma and Immunology Foundation; Allergist and Immunologist</td>
</tr>
<tr>
<td>Elinor Wilson</td>
<td>President and CEO, Assisted Human Reproduction Canada</td>
</tr>
<tr>
<td>Tia Moffat</td>
<td>Senior Program Manager, NCE Program, ex-officio</td>
</tr>
<tr>
<td>Jennifer Protudjer</td>
<td>President, AllerGen Student and New Professionals Network (ASNPN), ex-officio</td>
</tr>
<tr>
<td>Diana Royce</td>
<td>Managing Director and COO, AllerGen NCE Inc., ex-officio</td>
</tr>
</tbody>
</table>

## Research Management Committee (RMC) Membership

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allan Becker</td>
<td>Professor, University of Manitoba</td>
</tr>
<tr>
<td>Dean Befus</td>
<td>Professor, University of Alberta</td>
</tr>
<tr>
<td>Jeffrey Brook</td>
<td>Professor, University of Toronto; Senior Scientist, Air Quality Research Branch, Environment Canada</td>
</tr>
<tr>
<td>Tim Caulfield</td>
<td>Research Director, Health Law Institute, University of Alberta</td>
</tr>
<tr>
<td>Judah Denburg</td>
<td>Chair, Scientific Director and CEO, AllerGen NCE Inc.</td>
</tr>
<tr>
<td>Susan Elliott</td>
<td>Professor and Dean, University of Waterloo</td>
</tr>
<tr>
<td>Patricia Lorenz</td>
<td>President, Sedulous Investments</td>
</tr>
<tr>
<td>Paul O’Byrne</td>
<td>Professor and Chair of Medicine, McMaster University</td>
</tr>
<tr>
<td>Peter Paré</td>
<td>Professor, University of British Columbia</td>
</tr>
<tr>
<td>David Prefontaine</td>
<td>Vice President, AllerGen Student and New Professional Network (ASNPN)</td>
</tr>
<tr>
<td>Mark Raizenne</td>
<td>Director General, Public Health Agency of Canada</td>
</tr>
<tr>
<td>Malcolm Sears</td>
<td>Professor, McMaster University</td>
</tr>
<tr>
<td>David Shindler</td>
<td>Executive Director, BioDiscovery Toronto (Inc.)</td>
</tr>
<tr>
<td>Brian Underdown</td>
<td>Managing Director, Lumira Capital</td>
</tr>
<tr>
<td>Tia Moffat</td>
<td>Senior Program Manager, Networks of Centres of Excellence (ex officio)</td>
</tr>
<tr>
<td>Diana Royce</td>
<td>Managing Director and COO, AllerGen NCE Inc. (ex officio)</td>
</tr>
</tbody>
</table>

## Network-Supported Intellectual Property (NSIP) Advisory Committee Membership

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dean Befus</td>
<td>Professor, University of Alberta</td>
</tr>
<tr>
<td>Terry Delovitch</td>
<td>Senior Scientist, Robarts Research Institute</td>
</tr>
<tr>
<td>Judah Denburg</td>
<td>Scientific Director and CEO, AllerGen NCE Inc.</td>
</tr>
<tr>
<td>John-Paul Heale</td>
<td>Associate Director, University of British Columbia</td>
</tr>
<tr>
<td>Patricia Lorenz</td>
<td>President, Sedulous Investments</td>
</tr>
</tbody>
</table>
Board of Directors

Graham Scott, C.M., Q.C.
Toronto, ON

Claude Roy, MD, FRCP(C)
Montreal, QC

Judah Denburg, MD, FRCP(C)
Hamilton, ON

Douglas Barber, PhD
Hamilton, ON

Howard Bergman, MD, FRCP(C)
Montreal, QC

Mark Bisby, DPhil
Ottawa, ON

Zave Chad, MD, FRCP(C)
Ottawa, ON

Deborah Danoff, MD, FRCP(C)
Ottawa, ON

Kevin Fehr, PhD
Toronto, ON

Gail Gauvreau, PhD
Hamilton, ON

Peter George, CM, O.Ont
Hamilton, ON

Christine Hampson, PhD
Toronto, ON

Eric Leith, MD, FRCP(C)
Oakville, ON

Elinor Wilson, PhD
Ottawa, ON

Tia Moffat, PhD
Ottawa, ON

Jennifer Protudjer, MSc
Winnipeg, MB

Diana Royce, EdD
Hamilton, ON
Diana Royce  Chair, Managing Director and COO, AllerGen NCE Inc.
Brian Underdown  Managing Director, Lumira Capital

**Policy, Ethics, Law and Society (PELS) Committee Membership**

- Michael Abbott  Program Manager, Health Canada
- Tim Caulfield  Research Director, Health Law Institute, University of Alberta (Chair)
- Lisa Cicutto  Associate Professor, University of Toronto
- Susan Elliott  Professor and Dean, University of Waterloo
- Alina Gildiner  Assistant Professor, McMaster University
- Samuel Godefroy  Director General, Health Canada
- Christine Hampson  President and CEO, The Asthma Society of Canada
- Anthony Levinson  Associate Professor, McMaster University
- Diane Lougheed  Professor, Queen’s University
- Mark Raizenne  Director General, Public Health Agency of Canada
- Diana Royce  Managing Director and COO, AllerGen NCE Inc., ex officio
- Elinor Wilson  President and CEO, Assisted Human Reproduction Canada

**AllerGen Student and New Professionals Network (ASNPN) Executive**

- President  Jennifer Protudjer, University of Manitoba
- Vice-President  David Préfontaine, McGill University
- Past-President  Michelle North, University of Toronto
- Secretary/Treasurer  Umme Akhtar, University of Toronto
- Regional Director, Ontario  Victoria Arrandale, University of Toronto
- Regional Director, Quebec/Atlantic  Lianne Soller, McGill University
- Regional Director, Pacific West Central  Steven Maltby, University of British Columbia
- Events/Communications  Kathleen Fraser, Queen’s University

**Administrative Centre**

- Judah Denburg  Scientific Director and CEO
- Diana Royce  Managing Director and COO
- Mark Mitchell  Manager, Research and Partnerships
- Jordan Moore  Manager, Communications
- Liz Dzaman  Executive Assistant and Corporate Secretary
- Anne Painter  Finance Officer
- Melissa Shuker  Programme Coordinator
- Maggie Civak  Research Coordinator
- Kim Westmoreland  Administrative Assistant

**Advanced Education and Training Opportunities Advisory Committee (AETOAC) Membership**

- Thomas Issekutz  Dalhousie University
- Oxana Latycheva  The Asthma Society of Canada
- Irvin Mayers  University of Alberta
- Chris Mody  University of Calgary (Chair)
- Michelle North  University of Toronto & President, ASNPN
- Jennifer Protudjer  President, AllerGen Student and New Professionals Network (ASNPN)